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ABSTRACT 
Neurodegenerative disorders are chronic, progressive, and often fatal disorders of 
the nervous system caused by dysfunction, and ultimately, death of neuronal cells. 
The underlying mechanisms of neurodegeneration are poorly understood, and 
monogenic disorders can be utilised as disease models to elucidate the pathogenesis.  
Juvenile neuronal ceroid-lipofuscinosis (JNCL, Batten disease) is a recessively 
inherited lysosomal storage disorder with progressive neurodegeneration and 
accumulation of autofluorescent storage material in most tissues. It is caused by 
mutations in the CLN3 gene, but the exact function of the corresponding CLN3 
protein, as well as the molecular mechanisms of JNCL pathogenesis have remained 
elusive. JNCL disease exclusively affects the central nervous system leaving other 
organs unaffected, and therefore it is of a particular importance to conduct studies in 
brain tissue and neuronal cells. 
The aim of this thesis project was to elucidate the molecular and cell biological 
mechanisms underlying JNCL. This was the first study to describe the endogenous 
Cln3 protein, and it was shown that Cln3 localised to neuronal cells in the mouse 
brain. At a subcellular level, endogenous Cln3 was localised to the presynaptic 
terminals and to the synaptosome compartment, but not to the synaptic vesicles. 
Studies with the CLN3-deficient cells demonstrated an impaired endocytic 
membrane trafficking, and established an interconnection between CLN3, 
microtubulus-binding Hook1 and Rab proteins. This novel data was not only 
important in characterising the roles of CLN3 in cells, but also provided significant 
information delineating the versatile role of the Rab proteins. To identify affected 
cellular pathways in JNCL, global gene expression profiling of the knock-out mouse 
Cln3-/- neurons was performed and systematically analysed; this revealed a slight 
dysfunction of the mitochondria, cytoskeletal abnormality in the microtubule plus-
end, and an impaired recovery from depolarizing stimulus when specific N-type 
Ca2+ channels were inhibited, thus leading to a prolonged time of higher intracellular 
7Ca2+. All these defective pathways are interrelated, and may together be sufficient to 
iniate the neurodegenerative process. Results of this thesis also suggest that in 
neuronal cells, CLN3 most likely functions at endocytic vesicles at the presynaptic 
terminal, potentially involved in the regulation of the calcium-mediated synaptic 
transmission. 
Keywords: neurodegeneration, lysosomal storage disorder, neuronal ceroid 
lipofuscinosis, lysosome, microtubulus, endocytosis, intracellular membrane 
trafficking
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TIIVISTELMÄ 
Hermoston rappeumasairaudet ovat kroonisia, eteneviä ja usein kuolemaan johtavia 
tauteja, jotka johtuvat hermosolujen toimintahäiriöistä ja kuolemasta. 
Hermosolurappeuman tarkat mekanismit ovat huonosti tunnettuja ja yhden 
geenivirheen aiheuttamat monogeeniset taudit voivat toimia tautimalleina 
patogeneesin selvittämisessä.   
Juveniili neuronaalinen seroidi-lipofuskinoosi (JNCL, Battenin tauti) on peittyvästi 
periytyvä lysosomaalinen kertymätauti, jonka tyypillisiä piirteitä ovat etenevä 
keskushermoston hermosolujen rappeuma ja autofluoresoivan materiaalin 
kertyminen useimpiin kudoksiin. JNCL johtuu virheistä CLN3-geenissä, mutta 
vastaavan CLN3-proteiinin toiminta ja JNCL-taudin syntymekanismit ovat 
tuntemattomia. Taudin oireet keskittyvät yksinomaan keskushermostoon ja siksi on 
tärkeää tutkia tautia aivokudoksessa ja hermosoluissa.     
Tämän väitöskirjaprojektin tavoitteena oli valottaa JNCL-taudin solu- ja 
molekyylitason tautimekanismeja erilaisissa solumalleissa. Työssä kuvailtiin 
ensimmäistä kertaa hiiren Cln3-proteiinin paikantumista aivoissa ja hermosoluissa.  
Cln3 paikantui kudostasolla hermosoluihin ja hermosoluissa pre-synaptiselle 
alueelle, synaptosomiin, mutta ei varsinaisiin synaptisiin vesikkeleihin. Kokeet 
CLN3-puutteisilla soluilla osoittivat solutason häiriön endosyyttisessä 
kalvoliikenteessä ja yhdistivät CLN3-proteiinin solun mikrotubulus-tukirankaan. 
Tutkimuksessa saatiin myös tärkeää tietoa solun kalvoliikenteessä toimivien Rab-
proteiinien toiminnasta. JNCL-taudissa tärkeitä metaboliareittejä tutkittiin 
vertailemalla geeni-ilmentymistä poistogeenisen Cln3-/- hiiren hermosoluisssa ja 
normaaleissa kontrolleissa mikrosiruanalyysin avulla. Löydökset viittasivat lievään 
alentumaan mitokondrion hengitysketjun toiminnassa ja poikkeavuuteen solun 
tukirangassa. Lisäksi havaittiin häiriö kalsiumvälitteisen hermoimpulssin säätelyssä, 
mikä voi johtaa pidentyneeseen korkeaan solunsisäiseen Ca2+-tasoon. Nämä 
solunsisäiset metaboliareitit ovat liittyneet toisiinsa ja niiden yhtäaikainen 
9toimintahäiriö voi johtaa hermosolujen rappeumamekanismien aktivoitumiseen. 
Väitöskirjatyön tulokset viittaavat siihen, että CLN3 todennäköisesti toimii 
endosyyttisissä vesikkeleissä hermosolujen presynaptisella alueella ja mahdollisesti 
osallistuu kalsiumvälitteisen hermoimpulssin säätelyyn.  
Avansanat: neurodegeneraatio, lysosomaaliset kertymätaudit, neuronaalinen seroidi-
lipofuskinoosi, lysosomi, mikrotubulus, endosytoosi, solunsisäinen kalvoliikenne,  
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INTRODUCTION 
Neurodegenerative disorders are a diverse group of acquired and inherited diseases 
of the nervous system. They are chronic, progressive and cannot be curably treated; 
thus they are associated with substantial morbidity, mortality, and great importance 
medically, socially and financially. Pathologically, the neurodegenerative diseases 
are characterised by the death of specific neuron populations at specific regions of 
the central or peripheral nervous system, and the individual pattern of this 
deterioration creates the specific clinical characteristics of each disease. There is, 
however, little understanding of the underlying pathogenetic processes and 
mechanisms of the neuronal death. Monogenic diseases, such as the lysosomal 
storage disorders and the neuronal ceroid lipofuscinoses, serve as disease models for 
studies on neuronal death in complex neurodegenerative disorders, and thus provide 
novel avenues for therapeutic intervention.   
Juvenile neuronal ceroid lipofuscinosis (JNCL, Batten disease, or Spielmeyer-Vogt- 
Sjögren disease) is the most common neurodegenerative disease of childhood 
(Santavuori, et al., 2000). This autosomal recessively inherited disease is caused by 
mutations in the CLN3 gene, identified in 1995 by the International Batten Disease 
Consortium (Consortium, 1995). It is particularly enriched in Finland, and is part of 
the Finnish disease heritage (Norio, 2003). JNCL is classified as a lysosomal storage 
disorder (LSD), and it also belongs to a group of at least eight inherited progressive 
neurodegenerative diseases called neuronal ceroid lipofuscinoses (NCLs) (Haltia, 
2003). NCL diseases are marked by two histopathological findings: degeneration of 
nerve cells, foremost in the cerebral cortex, and accumulation of autofluorescent 
ceroid-lipopigment in both neural and peripheral tissues (Goebel, 1997). In JNCL, 
the ultrastructure of the autofluorescent inclusions resembles a fingerprint and the 
major storage component is identified as mitochondrial ATP synthase subunit c  
(Palmer, et al., 1992).  
Clinical features of JNCL include visual failure, epileptic seizures and progressive 
psychomotor degeneration, which lead to premature death at the age of 18-30 years 
(Santavuori, 1988). Most patients carry a 1.0-kb deletion of the CLN3 coding 
region; in addition 40 mutations and 2 polymorphisms have been characterised 
(NCL Mutation Database). The corresponding CLN3 protein is an integral 
membrane protein with 5-6 transmembrane domains and two lysosomal targeting 
motifs (Ezaki, et al., 2003; Kyttala, et al., 2004).  The function of CLN3 has 
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remained elusive, but its evolutionary conservation among species from yeast to 
humans indicates a fundamental role in the cell metabolism.  
JNCL disease specifically affects neuronal cells and leaves other organs clinically 
unaffected, and hence it is of utmost importance to approach the disease mechanism 
by studying the expression and localisation of CLN3 in the brain and neuronal cells. 
The aim of this thesis was to elucidate the molecular and cell biological properties of 
the CLN3 protein in neuronal and patient cells and tissues, with the ultimate goal of 
enhancing the understanding of the vital function of CLN3, and the mechanisms of 
neurodegeneration. This will provide the basis for the development of novel 
treatment strategies for these devastating diseases.  
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REVIEW OF THE LITERATURE 
1. Intracellular membrane trafficking 
1.1 Principles of intracellular membrane trafficking 
Intracellular membrane trafficking can be divided into two distinct pathways; the 
biosynthetic/secretory pathway and the endocytic pathway (Figure 1). In the 
secretory pathway, the newly synthesized proteins, carbohydrates and lipids are 
transported through the endoplasmic reticulum (ER) and Golgi to the cell surface 
(constitutive secretory pathway), or to the endosomes/lysosomes. Endocytic 
pathway accommodates the internalization of macromolecules, solutes or pathogens 
into the cells, and will be discussed in detail below (Chapter 1.2). Transport routes 
form connections between the biosynthetic/secretory and endocytic pathways at the 
level of the Golgi apparatus and the endocytic compartments (Gruenberg and 
Maxfield, 1995).  
Figure 1. Schematic representation of the major pathways in intracellular 
membrane trafficking. The arrows represent known or presumed transport 
routes. The coat complexes are indicated with colours; COPII (blue), COPI 
(red), and clathrin (yellow). ECV/MVB, endocytic carrier 
vesicle/multivesicular body. Modified from Bonifacino et al., 2004, and 
Gruenberg, 2001.  
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Characteristic of eukaryotic cells is their ability to compartmentalize functions into 
membrane bound organelles. Transport between these organelles occurs via 
membrane-enclosed transport intermediates, or vesicles. This vesicle-transport 
hypothesis was formulated from early electron microscopy findings (Palade, 1975). 
It postulated that vesicles bud off the donor compartment (vesicle budding) in a 
process associated with molecular sorting (or protein sorting), which allows the 
selective inclusion or exclusion of individual membrane and content proteins during 
the formation of vesicle, and the ability to segregate the vesicular container from its 
cargo after vesicle fusion. The transport vesicles are subsequently targeted to their 
specific acceptor compartment (vesicle targeting), where they undergo fusion with 
the acceptor membrane (vesicle fusion), and unload their cargo. The segregated 
processes allow the consequent recycling or release of the components involved in 
the vesicle formation and targeting, which may then be returned back to the donor 
compartment (Bonifacino and Glick, 2004; Mellman and Warren, 2000).  
The selective incorporation of cargo and the budding of transport vesicles are 
mediated by protein coats. These coats deform the flat membrane sites into round 
structures that are eventually released as coated transport vesicles. The coats also 
actively participate in cargo selection, and potentially function in post-budding 
events by recruiting accessory factors that mediate interactions with the cytoskeleton 
and tethering factors (Bonifacino and Lippincott-Schwartz, 2003). The first coat to 
be identified was clathrin (Pearce, 1975; Roth and Porter, 1964), that functions in 
post-Golgi locations within the cells, including the plasma membrane, trans-Golgi
network (TGN), and endosomes. Clathrin binds to its target membranes in 
conjunction with one of its several adaptor complexes. Arf-GTP and/or specific 
phosphoinositides recruit the cytosolic clathrin adaptors in a specific combination to 
a particular membrane, to which clathrin is consequently recruited to form the 
spherical, cage-like lattice (Kirchhausen, 2000; Kirchhausen and Harrison, 1981). 
Known adaptors of clathrin include the heterotetrameric adaptor proteins (AP), 
monomeric GGAs (Golgi-localized, γ-ear-containing, ADP-ribosylation factor-
binding proteins), Hrs (hepatocyte growth factor-regulated tyrosine kinase 
substrate), Epsin 1 and Eps15 (epidermal growth factor receptor substrate 15) 
(Reviewed in (Bonifacino and Lippincott-Schwartz, 2003). Non-clathrin coats 
typically facilitate vesicular transport in the early secretory pathway (Barlowe, et al., 
1994; Waters, et al., 1991). COPII is the best characterized of these, and it mediates 
the anterograde transport from ER to either ER-Golgi intermediate compartment 
(ERGIC) or the Golgi complex (Barlowe, et al., 1994). COPI functions mainly in the 
retrograde transport within the Golgi complex and from the Golgi to the ER 
(Letourneur, et al., 1994) but may also act at the level of endosomes (Oprins, et al., 
1993).  
19
The principle of vesicle targeting describes the process, in which the vesicles 
emerging from the donor compartment bear “an address tag” that permits their 
docking and fusion only with the appropriate acceptor compartment. The core 
processes seem to be similar in all intracellular fusion with the exception of fusion 
of mitochondria and peroxisomes, which proceed via different processes (Hermann, 
et al., 1998; Sesaki and Jensen, 2001; Titorenko and Rachubinski, 2000). The first 
step in intracellular vesicle fusion is to recognise the appropriate partner membrane, 
and this process is variably called membrane attachment, or tethering and docking. 
Central in membrane attachment are the Rab GTPases that are localised to specific 
intracellular compartments and may serve as identity markers for them. Other 
tethering factors have also been identified (Whyte and Munro, 2002). The Rab 
GTPase family consists of over 60 members in humans and they cycle between the 
active, membrane bound GTP- and the inactive, soluble GDP-bound states in 
response to regulating factors (Stenmark and Olkkonen, 2001; Zerial and McBride, 
2001). Rab proteins act directionally; they are localised to the donor membrane in 
order to mediate its association to the target membrane. The GDP-bound Rabs form 
soluble, cytosolic complexes with GDI (GDP dissociation inhibitor)  (Araki, et al., 
1990). The GDP-Rab complexes are activated by the action of GEFs (guanine-
nucleotide exchange factor), which exchange the GDP to GTP; this is also 
associated with the membrane attachment of Rabs via the hydrophobic 
geranylgeranylgroups (Zerial and McBride, 2001). When donor and acceptor 
membranes are brought to close proximity, the GTP-bound Rabs recruit their 
specific effector molecules to form large complexes that facilitate the membrane 
attachment. After the fusion, a Rab GTPase activating protein (GAP) activates the 
hydrolysis of GTP, and the resulting GDP-bound Rab is recognised by the GDI, 
which detaches it from the membrane (Dirac-Svejstrup, et al., 1997). Rab effectors, 
that by definition bind only the active GTP-bound Rab proteins, form a structurally 
heterogenous and fast-growing family. The variation and large number of the 
effector molecules for individual Rabs indicate a high degree of specialization in 
function for an individual organelle and transport process. In addition to membrane 
attachment, the Rab proteins have been reported to function in vesicle budding, for 
example Rab9 is required for the transport from late endosomes to TGN, and Rab1 
may have a role in the vesicle budding from the ER (Barbero, et al., 2002; Nuoffer, 
et al., 1994). Recently interactions with cytoskeletal components and Rab proteins 
have been reported delineating the multifunctional role of the Rab protein family 
(e.g. (Echard, et al., 1998; Nielsen, et al., 1999; Young, et al., 2005).      
After the donor and acceptor membranes are attached, the fusion reaction is initiated 
by interactions of the SNARE (SNAP receptor) and SM (Sec1/Munc18-like) 
proteins. Remarkably, both the specific targeting and the fusion reactions rely on the 
same class of proteins, the organelle-specific family of SNARE proteins (Rothman, 
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1994). The original SNARE hypothesis stated that transport vehicles carry a specific 
v-SNARE that binds to the cognate t-SNARE on the target membrane (Figure 2). 
The SNARE family of proteins is variable in structure and size, but all bear a 
homologous SNARE motif containing 60-70 aa that include typical coiled coil 
repeats. Most SNAREs also contain a C-terminal transmembrane domain for 
membrane attachment (Bock, et al., 2001).  Pairing of the cognate v- and t-SNAREs 
produces a very stable four helix bundle, a trans-SNARE complex that bridges the 
fusing membranes (Hanson, et al., 1997; Lin and Scheller, 1997; Sutton, et al., 
1998). After the fusion, the SNAREs are present in the same membrane in a cis-
complex. The fusion complex is dissociated and the SNAREs are recycled by the 
action of the NSF (N-ethyl-maleimide sensitive fusion protein) ATPase and the 
soluble NSF-attachment proteins (SNAP) (Mayer, et al., 1996; Sollner, et al., 1993). 
According to the SNARE model, one ?-helix is contributed by the v-SNARE 
(VAMP/synaptobrevin or a protein related to them) and the other three ?-helices 
come from the oligomeric t-SNARE (Sutton, et al., 1998). The t-SNARE usually 
consists of three separate polypeptides, of which one is homologous to syntaxin, one 
to the N-terminus of SNAP-25, and one to the C-terminus of SNAP-25. The 
observation that the centre of the helix bundle is composed of four highly conserved 
amino acids, three glutamines (Q) and one arginine (R), led to specific renaming of 
the SNAREs to Q-SNAREs and R-SNAREs, which roughly correspond to the t- and 
v-SNAREs, respectively (Fasshauer, et al., 1998). Furthermore, it has become clear 
that the original v- and t-SNARE model may be misleading and too simplistic to 
explain all fusion reactions. For example, trans-SNARE complexes can also be 
formed in fusion from two pairs of transmembrane SNAREs on both fusing 
membranes (Cao and Barlowe, 2000). Thus, currently the SNARE components are 
usually referred as R-SNAREs (VAMPs), Qa-SNAREs (syntaxins), Qb-SNAREs (N-
terminal SNAP-25 motif), and Qc-SNAREs (C-terminal SNAP-25 motif) (Figure 2).  
Figure 2. Schematic presentation of the formation of the SNARE complex.  
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The SNARE proteins themselves are not sufficient, however, to trigger the 
membrane fusion reaction. Studies with knock-out mice models revealed that the 
deletion of the R-SNARE synaptobrevin/VAMP did not entirely abolish the synaptic 
exocytosis (Schoch, et al., 2001), whereas the deletion of the Munc18-1 eliminated 
the release completely (Verhage, et al., 2000). It therefore seems that the action of 
the SM family (Sec1/Munc18-like proteins) is more fundamental to membrane 
fusion. The SM proteins are cytosolic proteins of 650-700 residues (Jahn and 
Sudhof, 1999), and most of them interact with the SNARE proteins by a direct 
binding to their specific syntaxin (Qa-SNARE) (Toonen and Verhage, 2003). No 
universal principle for the action of the SM proteins seems to exist, but most 
evidence suggests that the SM proteins regulate the SNARE assembly in a manner 
coupled to the membrane attachment (Jahn, et al., 2003). It is also likely that the SM 
proteins function as a link between the SNARE complex and the Rab effectors and 
other tethering factors (Kauppi, et al., 2004). 
1.2 Pathways of endocytosis 
Small essential molecules, such as amino acids, carbohydrates and ions, can pass the 
plasma membrane through the action of their specific integral membrane channels or 
pumps. In contrast, larger macromolecules must be internalized into the cells 
through a process called endocytosis, in which the plasma membrane invaginates 
and pinches off as transport vesicles. Two basic forms of endocytosis exist; 
phagocytosis (“cell eating”) and pinocytosis (“cell drinking”, also called fluid phase 
endocytosis) (Conner and Schmid, 2003; Mellman, 1996).  
Phagocytosis refers to the internalization of large particles (diameter >0.5 μm), 
usually pathogens (e.g. bacteria and yeast), or large debris (apoptotic cells, deposits 
of fat) by specialized cells, such as macrophages, monocytes and neutrophils 
(Aderem and Underhill, 1999). Phagocytosis is a cargo-stimulated process, in which 
the particles to be ingested must first bind to specific plasma membrane receptors 
that are capable of activating their own uptake in an actin-dependent manner. Rho-
family of GTPases are central players in the down-stream signalling cascades and 
often also able to activate the cells’ own inflammatory responses (Hall and Nobes, 
2000). Under most circumstances the phagocytosed vesicles, phagosomes, fuse with 
endosomes and/or lysosomes (Kielian and Cohn, 1980), which allows the lysosomal 
degradation, and the presentation of the processed pathogen peptides on the cell 
surface, in order to activate humoral immune response. Some pathogens are able to 
utilize the phagocytotic pathway to enter the cells and replicate in the phagosomes. 
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For example, mycobacteria are able to reproduce in the acidic phagosomes and 
escape from the degradative pathway (Steele-Mortimer, et al., 2000).      
Pinocytosis is divided into four basic types based on the entry mechanism; 
macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
and clathrin- and caveolae-independent endocytosis. The macropinocytic vesicles 
are generally over 1 μm in diameter, while the other types of pinocytic vesicles are 
considerably smaller (diameter <0.2 μm) (Mellman, 1996). Mechanistically, 
macropinocytosis resembles phagocytosis in that it is actin-dependent and involves 
the Rho-family of GTPases. However, the vesicle formation differs; in phagocytosis, 
the plasma membrane “climbs up” to surround the cargo, whereas in 
macropinocytosis the plasma membrane protrusions collapse and fuse back to the 
membrane. Macropinocytosis is an effective way to internalise large volumes of 
extracellular environment, however, the regulation and nature of this fusion is to a 
great extent unclear. It can be transiently induced and may have a role in the down-
regulation of activated signalling molecules (Conner and Schmid, 2003). In addition,  
dendritic cells use macropinocytosis to screen large volumes of extracellular milieu 
(Mellman and Steinman, 2001).      
Clathrin-mediated endocytosis is the best characterized of the endocytic pathways. It 
was earlier referred to as “receptor-mediated endocytosis”, which turned out to be a 
misnomer, as also other pinocytic pathways involve interactions of specific ligands 
and receptors. Clathrin-mediated endocytosis is constitutive and occurs in all 
mammalian cells. It functions in the continuous uptake of nutrients and signalling 
molecules and is essential for tissue and organ development, and throughout the life 
of an organism (Di Fiore and De Camilli, 2001; Mellman, 1996; Seto, et al., 2002). 
Clathrin-mediated endocytosis is initiated when ligand-transmembrane receptor 
complexes concentrate on the “coated pits” on the plasma membrane. The coated 
pits are composed of clathrin triskelions assembled into a polygonal lattice, 
accompanied by a heterotetrameric AP-2 adaptor complex.  A multidomain GTPase 
dynamin mediates the fission of the coated pit leading to the release of the clathrin-
coated vesicle (CCV). Dynamin is shown to be involved in a similar scission step 
also in phagocytosis, caveolae-mediated endocytosis as well as in some clathrin- and 
caveolae-independent pathways (Hinshaw, 2000; Sever, et al., 2000). Interactions 
with the actin cytoskeleton are important but non-essential for clathrin-mediated 
endocytosis in mammals (Fujimoto, et al., 2000). It has been suggested that the actin 
network functions in spatial organisation of the “endocytic hotspots”, from which 
CCVs emerge (Gaidarov, et al., 1999). Scaffolding proteins such as ampiphysin, 
Eps15 and intersectin, comprise multiple domains for protein and lipid interaction, 
and connect the endocytic machinery to the actin cytoskeleton and perhaps also to 
other intracellular trafficking events. In addition, the clathrin-mediated endocytic 
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pathway is regulated at least by phosphorylation, receptor signalling and lipid 
modifications. A plethora of accessory factors have been implicated, and they are 
extensively reviewed elsewhere (Brodsky, et al., 2001; Slepnev and De Camilli, 
2000).    
Caveolae, flask-shaped plasma membrane invaginations of 50–80 nm in diameter 
(Palade, 1953) have been shown to be directly involved in one type of clathrin-
independent endocytosis, now referred to as caveolae-mediated endocytosis. 
Caveolae are rich in cholesterol and sphingolipids, the “raft lipids” (Simons and 
Toomre, 2000), and their major structural component is caveolin-1 (caveolin-3 in 
muscle cells) (Rothberg, et al., 1992). The caveolins are essential for the formation 
and integrity of caveolae, and caveolin knock-out animals are devoid of caveolae 
(Drab, et al., 2001; Galbiati, et al., 2001; Razani, et al., 2001). They are however, 
viable and fertile, which indicates an ability of an organism to compensate for the 
loss of caveolae-mediated endocytosis. Caveolae-mediated endocytosis appears to 
be an inducible pathway, and it can be triggered by clustering of lipid raft 
components and MHC class I molecules on the plasma membrane, resulting in local 
signal transduction pathway activation and depolymerization of the cortical actin 
cytoskeleton (Pelkmans, et al., 2002). Subsequently, actin- and dynamin-dependent 
invagination of caveolae occurs. Materials endocytosed via this pathway include 
extracellular ligands (folic acid, albumin, interleukin-2), membrane components 
(glycosphingolipids, glycosylphosphatidylinositol-anchored proteins), bacterial 
toxins (cholera toxin, tetanus toxin), and several nonenveloped viruses (Simian virus 
40, Polyoma virus, Echovirus 1) (Reviewed in (Pelkmans and Helenius, 2002). Live 
cell imaging studies visualizing the cell entry of Simian Virus 40 (SV40) showed 
that after internalization, the primary caveolar vesicles transfer their cargo to pre-
existing caveolin-1-positive organelles termed caveosomes (Pelkmans, et al., 2001). 
The caveosomes receive cargo exclusively from the caveolae-mediated pathway, but 
from caveosomes the material can be distributed to the ER and the Golgi (e.g. 
SV40). 
Clathrin- and caveolae-independent endocytic pathways have also been discovered. 
For example, interleukin-2 (IL-2) receptor on lymphocytes, associated with 
detergent-resistant lipid domains (rafts), is internalized independent of both clathrin 
and caveolin, but dependent of dynamin (Lamaze, et al., 2001). Similarly, analysis 
of SV40 trafficking in cells devoid of caveolin-1, demonstrated a rapid, novel 
pathway independent of caveolae, clathrin and dynamin II but dependent of 
cholesterol (Damm, et al., 2005). The internalized virus bypassed the conventional 
endocytic organelles (see paragraph below), and was transported in apparently novel 
non-endosomal, cytosolic organelles to the ER. The novel pathway merged with the 
caveolar pathway at the level of the caveosomes. The exact mechanisms and 
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physiological functions of these novel endocytic pathways are yet to be determined; 
however, it is clear that they provide an important alternative to the clathrin- and 
caveolae-mediated pathways. It has been proposed that the different endocytic 
pathways have evolved due to the need to regulate and coordinate pinocytosis 
precisely in terms of the more complex cellular physiology, such as signal 
transduction, development and modulation of the cell’s responses to and interaction 
with its environment (Conner and Schmid, 2003).   
After internalization, most of the endocytosed cargo is delivered to the early 
endosomes (EE), which serve as the first sorting station. From EEs they can either 
be recycled back (recycling endocytosis) to the PM via the recycling endosomes 
(RE). Classic examples of this route are the recycling of the transferrin receptor 
(TfR) (Bleil and Bretscher, 1982) and low-density lipoprotein receptor (LDLR) 
(Brown and Goldstein, 1979). Alternatively, cargo destined to degradation is 
delivered via the multivesicular carrier vesicles (ECVs/MVBs) and late endosomes 
(LE) to the lysosomes (degradative pathway), exemplified in the trafficking of the 
low-density lipoprotein (LDL) (Goldstein, et al., 1975) and epidermal growth factor 
(EGF) (Carpenter and Cohen, 1976). The transport after the actin-dependent 
internalization is primarily microtubule-dependent (Qualmann and Kessels, 2002).  
According to the classic vesicle-transport hypothesis (Griffiths and Gruenberg, 
1991; Palade, 1975), the endocytic organelles remain as stable compartments that 
exchange cargo while retaining their identity. Alternative maturation model depicts 
the organelles as mosaics of membrane domains that progressively change in 
composition (“mature”) as they traffic downstream the pathway (Helenius, et al., 
1983; Murphy, 1991).  In vivo live cell microscopy experiments have shown that 
Rab GTPases are central in organizing the endocytic pathway into a mosaic of 
biochemically and functionally distinct domains that co-operate with their effectors 
to create a restricted environment on the vesicle membrane. The recycling pathway 
is composed of three major populations of endocytic vesicles: one containing only 
Rab5, a second with Rab4 and Rab5, and a third containing Rab4 and Rab11 
(Sonnichsen, et al., 2000). Similarly, late endosomes contain both Rab7 and Rab9 
that occupy distinct and separate domains (Barbero, et al., 2002), and the cargo in 
the degradative pathway is first present in the Rab5-positive early endosomes and 
later appears in the Rab7-positive late endosomes. Some reconciliation of the two 
models, vesicle-transport and maturation, was brought by a recent study that showed 
that the progression from early endosomes to late endosomes was mechanistically 
achieved by a Rab replacement from Rab5 to Rab7 on the endosomal membrane, 
powered by a Rab7 GEF, the class C VPS/HOPS complex (Rink, et al., 2005).     
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1.3 Specific features of transport in neurons 
The essence of the nervous system is to function in signalling, or information 
transfer both intracellularly from one part of the cell to another, and intercellularly 
between cells. Neuronal cells have unique, highly polarized structure to 
accommodate these functions (Figure 3). A typical neuron consists of a cell body 
(soma), several thick, narrowing dendrites that are often branched, and a thin, long 
axon. The length of an axon can vary from micrometers to meters before terminating 
at a synapse (derived from a Greek word for “connect”), a specialized structure for 
the intercellular communication (Levitan and Kaczmarek, 1997).  
Most of the proteins needed in the axon and synaptic terminals are synthesized in the 
soma and transported along the axon in membranous organelles or protein 
complexes (Grafstein and Forman, 1980). Correct intraneural transport is 
fundamental to neuronal morphogenesis, function and survival, and many proteins 
are selectively transported either to the axons or dendrites (Hirokawa and Takemura, 
2005). In addition, several specific mRNAs are transported in large protein-RNA 
complexes into the dendrites to support local protein synthesis (Job and Eberwine, 
2001). Fast axonal transport at ~400 mm/day is utilized to transport membranous 
organelles, whereas cytoskeletal proteins are transported by slow axonal transport at 
~0.2-2.5 mm/day (Brady, 1985). Axonal transport vesicles and macromolecular 
complexes are mainly transported along microtubules, long polymers of ?- and β-
tubulin of a diameter of 25 nm that run in longitudinal orientations (Hirokawa, 
1998). The microtubules in axons harbour an intrinsic polarity with the growing 
Anterograde
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Figure 3. Schematic drawing of the typical features of a neuronal cell. 
Structures and organelles that are common to all cell types, such as the ER, 
Golgi complex, and mitochondria are not shown.   
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“plus ends” pointing in the direction of the synapses. In contrast, the microtubules in 
the dendrites have mixed polarity (Baas, et al., 1988; Burton and Paige, 1981). Actin 
filaments are abundant near the the plasma membrane and especially in the growth 
cones (Dillon and Goda, 2005). In addition to the microtubules, particularly large 
axons contain neurofilaments, intermediate filaments with a diameter of 10 nm 
(Hirokawa and Takemura, 2004).   Kinesin and dynein superfamily proteins function 
as molecular motors and facilitate the movement along the microtubules. 
Anterograde transport, from cell body to axons and dendrites towards the plus-end 
of microtubules, is mainly carried out by the kinesin superfamily of proteins (KIFs) 
(Aizawa, et al., 1992). In contrast, the retrograde transport, from the axonal and 
dendritic terminals to the cell body is mostly facilitated by the cytoplasmic minus-
end directed motors of the dynein family (Harada, et al., 1998; Vallee, et al., 1988). 
Neuronal polarity is dependent of selective transportation of cargoes to axons and 
dendrites. Several specific targeting mechanisms and signals have been identified. 
Palmitoylation of cysteine residues is sufficient for axonal targeting of GAP-43 
(growth-associated protein 43) (El-Husseini Ael, et al., 2001) and GAD65 
(glutamate decarboxylase 65), which synthesizes γ-aminobutyric acid (GABA) 
(Kanaani, et al., 2002). Axonal targeting of the shaker (KV1) family of voltage-gated 
potassium channels requires a conserved T1 tetramerization domain, also required 
for the formation of the central pore of the channel (Gu, et al., 2003). Transport to 
dendrites has been suggested to be analogous to the basolateral transport in polarized 
epithelial cells (Mostov, et al., 2003). For example, the tyrosine-based motifs at the 
cytoplasmic tails of the low-density lipoprotein (LDL) receptor and the transferrin 
receptor (TfR) function as signals for basolateral targeting in polarized epithelial 
cells as well as for dendritic targeting in cultured neurons (Burack, et al., 2000; 
Jareb and Banker, 1998). An evolutionarily conserved dileucine-based motif has 
also been identified as the dendritic targeting signal for the KV4 (Shal) family of 
voltage-gated potassium channels (Rivera, et al., 2003). In addition to the selective 
transportation, selective retention has been proposed as a means for maintaining 
polarity. According to this model, cargoes are transported non-selectively to both 
axons and dendrites, but selective endocytosis eliminates the undesired molecules. 
Conversely, the inhibition of the selective endocytosis keeps the desired cargo 
retained. For example, VAMP2 is first distributed to the surfaces of both axons and 
dendrites of cultured hippocampal neurons, but is then endocytosed from the 
dendritic membrane (Sampo, et al., 2003). The endocytotic signal at the cytoplasmic 
domain is responsible for the selective removal by endocytosis and the consequent 
localisation merely in axons, however, its exact mechanism of action is not known.  
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1.4 Synaptic transmission 
Synaptic transmission is initiated when an action potential, initiated in the cell body, 
travels to the presynaptic nerve terminal, induces the opening of the Ca2+ channels, 
and the resulting transient Ca2+ influx triggers neurotransmitter release to the 
synaptic cleft. The neurotransmitter molecules diffuse to the post-synaptic terminal, 
bind to their respective receptors, and transfer the signal to the post-synaptic neuron 
(Sudhof, 2004). The neurotransmitters are released via exocytosis of the synaptic 
vesicles (SVs), which are involved in all presynaptic functions, directly or indirectly. 
The SVs undergo a trafficking cycle in the presynaptic nerve terminal that involves 
several steps (Figure 4): (1) active transport of neurotransmitters into the SVs, (2) 
clustering of the SVs in front of the synaptic active zone (“reserve pool”), (3) 
docking of the vesicles at the active zone (“readily releasable pool”), (4) priming of 
the vesicles (5) to make them competent for the Ca2+ triggered fusion-pore opening. 
After the fusion-pore opening and the exocytosis of the neurotransmitters, the 
synaptic vesicles are endocytosed and recycled by three alternative routes: (6) “kiss-
and-stay”, (7) “kiss-and-run”, or clathrin-mediated endosomal recycling either 
directly (8) or via an endosomal intermediate (9).  
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The synaptic vesicles are the central organelles in the presynaptic neurotransmitter 
release, and the interaction of the SVs with the presynaptic active zone during 
exocytosis is thought to be the common final pathway to all nerve terminal functions 
(Sudhof, 2004).  The synaptic vesicles are small, relatively simple organelles with a 
diameter of ~40 nm. Their only known function is to take up and release 
neurotransmitters. The active transport of all neurotransmitters into the synaptic 
vesicles is accomplished by the action of a vacuolar proton pump that couples ATP 
hydrolysis to proton translocation, thus establishing an electrochemical gradient 
across the vesicle membrane (Figure 4, step 1) (Maycox, et al., 1988). The proton 
pump consists of two connected complexes; a peripheral complex that contains the 
Figure 4. The synaptic vesicle cycle, modified from Südhof, 2004. 
The steps 1-9 refer to the text. SV, synaptic vesicle; RRP, readily 
releasable pool. 
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ATPase activity and a integral membrane complex that facilitates the proton 
translocation (Perin, et al., 1991). Seven transporters representing four  
neurotransmitter groups utilize the electrochemical gradient to mediate the 
neurotransmitter uptake of the synaptic vesicles; three transporters to glutamate 
(VGlut1-3) (Fremeau, et al., 2002; Gras, et al., 2002; Schafer, et al., 2002; 
Takamori, et al., 2002), two for monoamines (catecholamines, histamine, 
serotonine) (Erickson, et al., 1992; Liu, et al., 1992), a single transporter for both 
GABA and glycine (McIntire, et al., 1997; Sagne, et al., 1997), and one for 
acetylcholine (Alfonso, et al., 1993; Roghani, et al., 1994; Varoqui, et al., 1994). In 
addition to the proteins involved in the neurotransmitter uptake, the synaptic vesicles 
contain a complex array of trafficking proteins that take part in the synaptic exo- and 
endocytosis and recycling discussed below.  
The membrane fusion during exocytosis follows the same principles that were 
reviewed in Chapter 1.1. The specific SNARE proteins involved in synaptic 
exocytosis are VAMP 1 and/or 2 (synaptobrevins) on synaptic vesicles, and syntaxin 
1 and SNAP-25 on the presynaptic membrane (Sollner, et al., 1993). The VAMPs 
act as R-SNAREs/v-SNAREs, and the t-SNARE complex is composed of syntaxin 1 
(Qa-SNARE motif), and SNAP-25, containing both Qb- and Qc-SNARE motifs. 
Small neuronal proteins called complexins bind to the synaptic SNARE core 
complex and are thought to stabilize it (McMahon, et al., 1995).  SM-protein 
Munc18-1 binds to syntaxin 1 and its dissociation from it is required for the synaptic 
vesicle fusion with the plasma membrane (Dulubova, et al., 1999). Synaptic vesicle 
proteins synaptophysin 1 and 2 are also thought to regulate the SNARE function via 
binding to the VAMPs (Calakos and Scheller, 1994; Edelmann, et al., 1995; 
Johnston and Sudhof, 1990; Washbourne, et al., 1995).  
After the synaptic vesicles have become docked and primed at the active zone 
(Figure 4 steps 3 and 4), voltage-gated Ca2+ channels open resulting in the fusion-
pore opening and exocytosis of the neurotransmitter (step 5). Mostly the Ca2+ influx 
occurs through the P/Q (CaV2.1) or N-type (CaV2.2) Ca2+ channels (Dietrich, et al., 
2003). The Ca2+ influx triggers at least two types of release; fast, synchronous and 
phasic (Sabatini and Regehr, 1996), and slower asynchronous release (Atluri and 
Regehr, 1998; Barrett and Stevens, 1972; Geppert, et al., 1994b; Goda and Stevens, 
1994). The activation of the fast exocytosis requires that Ca2+ ions bind to the Ca2+
sensor proteins called synaptotagmins 1 and 2 on the synaptic vesicles (Fernandez-
Chacon, et al., 2001; Geppert, et al., 1994b). The action of synaptotagmin 1 is 
understood in more detail; the Ca2+ binding causes synaptotagmin 1 to dissociate 
from the SNARE complex, to which it binds in the absence of Ca2+, and to bind to 
the phospholipids membranes. The insertion of synaptotagmin 1 onto the membrane 
and the consequent mechanical stress is hypothesised to destabilize the fusion 
30
intermediate and open the fusion pore (Sudhof, 2004). Triggering of the slow, 
asynchronous release is mechanistically less clear, but it has been suggested that the 
other members of the synaptotagmin family function as Ca2+ sensors either alone or 
in collaboration with synaptotagmin 1. Evidence for high Ca2+ affinity exists at least 
for the synaptotagmins 3, 6 and 7 (Sugita, et al., 2001; Sugita, et al., 2002).  
The synaptic vesicles also contain at least three different Rab proteins; Rab3 
(Rab3A-D) (Schluter, et al., 2002), Rab5 (Fischer von Mollard, et al., 1994) and 
Rab11 (Khvotchev, et al., 2003). These small GTPases mediate membrane 
attachment by interacting with specific effector molecules (see Chapter 1.1). Rab3 is 
attached to the synaptic vesicles in the GTP-bound state and is the most abundant of 
the Rabs in the synaptic vesicles (Geppert, et al., 1994a). Analysis of the knock-out 
mouse model of Rab3A revealed that the function of Rab3A is important in the late 
steps of exocytosis after clustering and docking of the vesicles (Geppert, et al., 
1997). Other synaptic vesicle proteins involved in the Ca2+ triggered exocytosis are 
the SV2s (SV2A-C) (Buckley and Kelly, 1985) that have shown to function as 
cation (most likely Ca2+) transporters in synaptic vesicles (Janz, et al., 1999). 
Integrity of the SVs is also maintained by the synapsin family of proteins (synapsins 
1-3), although their precise function is unknown. They are able to bind various 
components of the cytoskeleton, especially actin, and may act in anchoring the SV 
pool to the presynaptic vesicle cluster (Greengard, et al., 1994). However, the 
mature SV assembly contains hardly any cytoskeletal components, and therefore the 
exact function of the synapsins remains unsolved (Dunaevsky and Connor, 2000; 
Morales, et al., 2000; Zhang and Benson, 2001).     
The presynaptic active zone is located opposite to the synaptic cleft. It is an 
electron-dense area, composed of biochemically insoluble material (Akert, et al., 
1971). The main components include six large non-membrane proteins that form a 
giant complex at the active zone: Munc13s (Munc13-1, -2, -3) (Brose, et al., 1995) 
RIMs (Rab3-interacting molecules; RIM1?, 2?/?/γ/, 3γ, 4γ) (Wang, et al., 1997; 
Wang and Sudhof, 2003; Wang, et al., 2000), Piccolo (Cases-Langhoff, et al., 1996), 
Bassoon (tom Dieck, et al., 1998), ERCs (ELKS/Rab3-interacting molecule/CAST, 
ERC1b and ERC2) (Ohtsuka, et al., 2002), RIM-BPs (RIM-BP1-3) (Wang, et al., 
2000), and ?-liprins (Liprin ?1- ?4) (Schoch, et al., 2002). The RIMs are the central 
elements of the presynaptic active zones as they bind directly to Munc13, ERCs, 
RIM-BPs and ?-liprins. In addition, the ERCs bind to ?-liprins, Piccolo and 
Bassoon. The RIMs are linked to the synaptic vesicles via the GTP-dependent 
interaction to Rab3 and Ca2+-dependent interaction to synaptotagmin 1. They are 
also potentially linked to the SNAREs via binding to SNAP-25 and Munc13-1 
binding to syntaxin 1.   
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After exocytosis, synaptic vesicles are rapidly endocytosed and recycled (Figure 4, 
steps 6-9). According to the current view, three proposed endocytic pathways exist 
(Sudhof, 2004). The two fast pathways are clathrin-independent routes, in which the 
vesicles either remain at the active zone for reacidification and refilling without 
detachment (kiss-and-stay, step 6)  (Barker, et al., 1972) or are recycled locally 
(kiss-and-run, step 7) (Ceccarelli, et al., 1973). The slower pathway is dependent of 
the clathrin-mediated internalization (Heuser and Reese, 1973) followed by 
recycling either directly (step 8) or via an endocytic intermediate (step 9). Low 
stimulation frequency leads to the utilization of the fast pathways in order to recycle 
synaptic vesicles fast to the readily releasable pool, whereas at high frequency 
stimulation, the slower clathrin-dependent pathway is used. The physiological 
relevance of the clathrin-mediated endosomal pathway (step 9) has been questioned, 
as endosomes are scarcely observed in the nerve terminals by EM studies. Recently 
however, strong evidence for the relevance of this endocytic pathway has been 
presented. Firstly, obligatory synaptic vesicle components include proteins such as 
the SNARE protein Vti1a?, which functions in membrane fusion events at the 
endosomal and trans-Golgi level (Antonin, et al., 2000). Similarly, the presence of 
Rab5 and Rab11 on the SVs suggests that the synaptic vesicles undergo endosomal 
fusions during their cycle (Nielsen, et al., 2000; Nielsen, et al., 1999; 
Wucherpfennig, et al., 2003). The absence of the endosomes in the nerve terminal 
has been explained by their transient nature (Wucherpfennig, et al., 2003), and the 
nerve terminal has been showed to be enriched in proteins associated with clathrin-
mediated endocytosis, particularly those involved in the acceleration of this pathway 
(Sun, et al., 2002). Moreover, inhibition of endosome fusion using 
phosphatidylinositol 3-kinase blockers caused a significant impairment of 
neurotransmitter release (Rizzoli and Betz, 2002). The presynaptic endosomes as 
well as the synaptic vesicles are present in the synaptosome fraction. CLN3 resides 
in the synaptosome fraction but is not present in the synaptic vesicles, is thus 
potentially involved in the endocytic pathway of the nerve terminal.    
2. Lysosomes and lysosomal storage disorders
2.1 The lysosome turns fifty
Fifty years ago, experiments by Christian de Duve and colleagues, aiming at 
characterizing hepatic glucose 6-phosphatase, led to the accidental observation of an 
unrelated acid phosphatase of rat liver, which in turn paved the way to the discovery 
of membrane-limited digestive organelles, termed lysosomes (de Duve C, 1955). 
32
The term lysosome is derived from the Greek expression for a digestive body and 
they are defined as hydrolase-rich, acidic organelles that lack both the cation-
dependent (46 kD) and cation-independent (300 kD) mannose 6-phosphate receptors 
(MPRs) (Reviewed in (Eskelinen, et al., 2003). Lysosomes serve as an endpoint for 
various intracellular pathways, at which proteins from the degradative, endocytic, 
autophagic and secretory pathways are degraded or recycled (Kornfeld and 
Mellman, 1989). Lysosomes are capable of a direct fusion with the late endosomes 
to form a hybrid organelle (Mullock, et al., 1998), and they have been reported to 
function at least in the turnover of cellular proteins, down-regulation of surface 
receptors, release of endocytosed nutrients, inactivation of pathogenic organisms, 
repair of the plasma membrane and loading of processed antigens onto the MHC 
class II molecules (Eskelinen, et al., 2003).  
Morphology of the lysosomes is heterogenous due to the various cellular functions 
and variations in the intraluminal content, however, generally lysosomes are 
described as membranous organelles with a limiting, external membrane and 
intraluminal vesicles. Proteomic analyses and other studies have identified novel 
soluble lysosomal proteins and integral membrane proteins and the current 
estimation is that there are at least 50-60 soluble hydrolases (Journet, et al., 2002), 
and as many as 55 membrane-associated and 215 integral lysosomal membrane 
proteins (Bagshaw, et al., 2005).  Over 50% of the lysosomal membrane mass is 
composed of highly glycosylated membrane proteins, called LAMP-1 (LGP-A), 
LAMP-2 (LGP-B), LIMP-1 (CD-63), LIMP-2 (LGP85), which were originally 
thought to mechanically protect the membrane from the degradative lysosomal 
enzymes with the help of their heavy glycosylation (Kornfeld and Mellman, 1989) 
(Figure 5). They do indeed form a protective glycocalyx on the surface of the inner 
membrane but appear to have additional functions as well. LAMP-2, for example, is 
proposed to function as a receptor for cytosolic proteins to be degradated via their 
KFERQ-related motifs (Dice and Terlecky, 1990). An important minor protein of 
the lysosomal membrane is a V-type H+-ATPase, a 13-subunit membrane spanning 
complex responsible for the acidification of the lysosomal lumen by coupling ATP 
hydrolysis and proton translocation. Importance of specific transporter proteins in 
the lysosomal membrane has been particularly well demonstrated in the form of 
certain lysosomal storage disorders, in which an intralysosomal accumulation of 
retained metabolites is observed (see Chapter 2.2).  
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Figure 5. Major and disease-associated integral membrane proteins of the lysosome. 
Schematic representation of the topology modified from Eskelinen et al., 2003, 
except for NPC1 from Davies et al., 2000 (Davies and Ioannou, 2000). LAMP, 
lysosome-associated membrane protein; LIMP, lysosomal integral membrane 
protein. 
2.2 Targeting of lysosomal proteins 
Targeting of most soluble lysosomal proteins is dependent of the mannose 6-
phosphate residues attached to them within the Golgi apparatus, and the recognition 
of this signal by the mannose 6-phoshate receptors (MPR) located at the trans-Golgi 
network (TGN), which then mediates their delivery to the lysosomes (Kornfeld, 
1990). Low levels of the MPRs are also present at the plasma membrane. Two 
MPRs have been identified with a general structure of a type I transmembrane 
glycoprotein. A large cation-independent 300-kD MPR, which also binds insulin-
like growth factor II, and a smaller 46 kD cation-dependent MPR have overlapping 
functions (von Figura, 1991). The MPRs with the bound lysosomal enzymes are 
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packed into AP-1 containing, clathrin-coated vesicles (CCV) at the TGN, via the 
interaction of AP-1 and GGA (Golgi localized, gamma-adaptin ear homologous, 
ADP-ribosylation factor binding proteins), to be delivered to the early endosomal 
compartments. At a molecular level, the sequestration of the MPRs into the CCVs is 
mediated by the dileucine- and tyrosine-based motifs in their cytoplasmic segments 
that are recognized by GGA (Doray, et al., 2002). In the late endosomes, the 
acidification of the endosomal pH leads to the dissociation of the receptor from the 
lysosomal enzymes, and the MPRs are recycled back to the TGN by the action of 
TIP47 (tail-interacting protein of 47 kD) (Diaz and Pfeffer, 1998). The lysosomal 
enzymes are then transported to the lysosomes.  
Alternative mechanisms for targeting the soluble lysosomal proteins also exist and 
they were explored using a knock-out mouse deficient of both the 300-kD and 46-
kD MPRs (Dittmer, et al., 1999). It was found that the ability to transport Cathepsin 
D to the lysosomes independent of the MPRs was dependent of the cell type. 
Thymocytes were able to target the enzyme correctly via an alternative intracellular 
route, whereas hepatocytes and fibroblasts secreted the enzymes. However, 
hepatocytes were able to recapture a significant amount of the secreted enzymes.   
Targeting of lysosomal transmembrane proteins is more complex and diverse 
compared to the classic MPR-route. It is mostly mediated by short, linear sequences 
of amino acids within the cytosolic domains of the proteins. These motifs are not 
precisely conserved sequences but degenerate motifs of four to seven residues, of 
which the two or three critical residues are often bulky and hydrophobic (Bonifacino 
and Traub, 2003). Cytoplasmic tyrosine-based motifs were the first to be identified, 
and they are composed of either NPXY or YXXØ consensus, where N is asparagine, 
P proline, X any amino acid, Y tyrosine, and Ø an amino acid with bulky sidechain. 
The NPXY signal was the first tyrosine-based sorting signal to be found (Davis, et 
al., 1986), but later it has been shown to mediate only rapid internalisation of a 
subset of type I integral membrane proteins, such as the LDL receptor, and not other 
intracellular events. In contrast, the YXXØ signals function in the sorting of a wide 
range of proteins, such as endocytic receptors (transferrin receptor), intracellular 
sorting receptors (mannose 6-phosphate receptors), TGN proteins (TGN38) 
(Canfield, et al., 1991; Jadot, et al., 1992),  as well as endosomal-lysosomal 
transmembrane proteins (Harter and Mellman, 1992; Williams and Fukuda, 1990). 
YXXØ appears to be an evolutionarily conserved sorting motif, and in the sorting of 
the lysosomal proteins, the Y residue is essential for function, the X residues tend to 
be acidic, and a glycine residue often precedes the critical tyrosine (Bonifacino and 
Traub, 2003). Examples of lysosomal proteins harbouring the YXXØ sorting motif 
include the major components of the lysosomal membrane, LAMP-1 and LAMP-2, 
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as well as LIMP-2 and cystinosin transporter (Bonifacino and Traub, 2003; Cherqui, 
et al., 2001; Rohrer, et al., 1996).       
Dileucine-based signals form the second major family of lysosomal transmembrane 
sorting signals. These signals match the consensus LL or LI, and substitution of 
either critical leucines with alanines impairs all signalling activities. The second 
leucine, however, can be replaced with isoleucine without a loss of activity. In 
addition, an acidic residue preceding the first leucine appears to be significant for 
lysosomal targeting (Bonifacino and Traub, 2003). Besides in lysosomal proteins 
such as NPC1 and LIMP-II (Sandoval, et al., 1994; Watari, et al., 1999), a dileucine-
based sorting signal exists in transmembrane proteins targeted to the synaptic dense-
core granules (VMAT1, VMAT2), stimulus-responsive storage vesicles (GLUT4), 
and melanosomes (tyrosinase) (Bonifacino and Traub, 2003).  
Both the tyrosine- and dileucine-based signals are recognized by cytoplasmic coat 
proteins that associate with the cytosolic side of the membrane. YXXØ and LL/LI 
are specifically recognized by the clathrin-associated adaptor protein (AP) 
complexes AP-1, AP-2, AP-3, and AP-4, although it seems that AP-3 is the main 
adaptor complex resposible for the lysosomal membrane protein targeting to the late 
endosomal pathway (Dell'Angelica, et al., 1999; Le Borgne, et al., 1998; Rous, et al., 
2002). Dispute over the clathrin-binding properties of AP-3 exists, but it was 
recently demonstrated that proteins with strong binding affinity to AP-3 are targeted 
directly from the TGN to the lysosomes, while most proteins trafficked via the 
plasma membrane and early endosomes (Ihrke, et al., 2004).  On the other hand, 
some LL signals are recognised by GGAs, and several proteins, such as clathrin, 
AP-2 and Dab2, have been suggested to function in the NPXY signal recognition, 
but the exact mechanisms remains unclear (Bonifacino and Traub, 2003). In most 
cases, regulation of the targeting signal recognition is achieved by phosphorylation. 
In addition, ubiquitination of cytosolic lysine residues has been shownt to act as a 
signal for sorting at various stages of the endosomal-lysosomal pathway (Bonifacino 
and Traub, 2003; Strous, et al., 1996). Conjugated ubiquitin is recognized by UIM 
(ubiquitin-interacting motif), UBA (ubiquitin-associated motif), or UBC (ubiquitin-
conjugating enzyme E2 motif) domains present within many components of the 
endosomal and lysosomal targeting machinery (Bonifacino and Traub, 2003). 
Moreover, some unconventional motifs for lysosomal membrane protein targeting 
have been found, e.g targeting of CLN3 requires both a conventional dileucine-
based motif as well as an unconventional M(X9)G motif in its carboxyl tail (Kyttala, 
et al., 2004). 
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2.3 Lysosomal storage disorders (LSDs) 
Lysosomal storage disorders (LSDs) are caused by a dysfunction of a lysosomal 
protein, which leads to the intralysosomal accumulation of undegraded metabolites. 
Most LSDs are present in infantile, juvenile and adult forms, of which the infantile 
forms are most severe, causing severe CNS symptoms and premature death. The 
adult forms are generally milder and peripheral symptoms play a major role in the 
course of the disease. Juvenile forms are often intermediate between these two 
(Futerman and van Meer, 2004).  LSDs are classified either based on the 
characterization of the defective enzyme or protein, or based on the accumulated 
substrate(s). The latter is most often used, although it may lead to false 
characterization of a disease, when the accumulating substance is identified prior to 
the identification of the defective protein. More than 40 LSDs are known, and they 
are classified into (1) sphingolipidoses, (2) mucopolysaccharidoses (MPS), (3) 
oligosaccharidoses and glycoproteinosis, (4) lipidoses, (5) diseases caused by 
defects in integral membrane proteins, and (6) others.  
Most mutations in classic lysosomal storage disorders cause a reduced enzymatic 
activity of a particular lysosomal hydrolase, or another protein that is required for an 
optimal enzyme activity (Futerman and van Meer, 2004). Misfolding of lysosomal 
proteins leading to their defective transport from the ER to the lysosomes can also 
underlie LSD. Defective transport from the ER to the lysosome due to an alternative 
mechanism is present in galactosialidosis, in which the formation of a multi-enzyme 
complex required for the transport of glycosidases is defective (Ostrowska, et al., 
2003).  A novel mechanism was identified, when the underlying defect for the 
multiple sulfatase deficient (MSD) was revealed. Mutations in the SUMF1 gene 
(sulphatase modifying factor-1) cause a production of a defective Cα-formylglycine-
generating enzyme (FGE). Defective FGE is unable to convert a specific Cys-
residue at the active site of the sulphatases, resulting in a delivery of multiple 
inactive sulphatases to the lysosomes, unable to perform their function in degrading 
sulphate esters (Dierks, et al., 2003). I-cell disease, on the other hand, is caused by a 
defective mannose 6-phosphate glycosylation in the Golgi, leading to the inability of 
the enzyme to bind the MPRs, which prevents their correct transport to the lysosome 
(Kornfeld and Sly, 2001).  
The topic of this thesis, the juvenile neuronal ceroid-lipofuscinosis (JNCL), belongs 
to the small group of LSDs caused by gene defects affecting integral lysosomal 
membrane proteins (Figure 5). Summary of the basic characteristics of this group 
are described in Table 1. Two of these disorders, cystinosin and the infantile sialic-
acid storage disease (ISSD)/Salla disease are caused by defects in transporters 
named cystinosin and sialin, respectively, that export soluble metabolites out of the 
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lysosome. Cystinosin transports cystine, a by-product of protein degradation, from 
lysosomes to the cytosol, where it is consequently reduced to the amino acid 
cysteine for further use. Defects in this transport result in the intra-lysosomal 
accumulation of cystine and wide spectrum of symptoms, whose presence is 
dependent on the type of mutation (Town, et al., 1998). The clinical symptoms 
include retinal degeneration, diabetes mellitus, hypothyreosis, and nephropathy 
(Attard, et al., 1999). Sialin is an anion transporter that transports free sialic acid out 
of the lysosomes, and consequently, defects cause an accumulation of free sialic acid 
in the lysosomes leading to neurodegeration manifested by an early onset 
developmental delay and ataxia (Verheijen, et al., 1999). Mutations in the major 
lysosomal protein LAMP-2 cause Danon disease (Nishino, et al., 2000), a 
cardioskeletal myopathy, is clinically characterized cardiomyopathy, myopathy, and 
variable mental retardation (Danon, et al., 1981). Defects in MCOLN1 gene 
encoding mucolipin-1 (MLN1) protein underlie mucolipidosis (ML) type IV, 
enriched in the Ashkenazi Jew population (Bargal, et al., 2000).  MLN1 is a non-
specific cation channel that shows topological similarities with calcium channel 
family called transient receptor potential (TRP) channels. The clinical symptoms 
include severe ophthalmologic abrnomalities (corneal opacities, retinal 
degeneration, strabismus), and psychomotor retardation (Berman, et al., 1974). 
Defects in two genes, NPC1 or NPC2, cause clinically and biochemically 
indistinguishable Niemann-Pick type C disease (NPC) (Carstea, et al., 1997; 
Naureckiene, et al., 2000). NPC1 protein is a lysosomal transmembrane protein with 
a sterol-sensing domain, whereas NPC2 is a soluble protein with cholesterol-binding 
properties (Reviewed in (Ikonen and Holtta-Vuori, 2004). NPC disease is classified 
as a cholesterol transport disorder; however, lysosomal accumulation of both 
cholesterol and sphingolipids occurs. Clinical symptoms are heterogeneous 
comprising of hepatic and neurodegenerative components, leading to premature 
death (Patterson, et al., 2001). 
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Table 1. Features of the diseases caused by defects in lysosomal membrane proteins. 
For references, see the text. *Defects in NPC2, a soluble lysosomal cholesterol 
binding protein (which is transported via the MPR-mediated route), can also cause 
NPC.
Diseases caused by defects in lysosomal membrane proteins
Disease Defective protein Main storage material 
Cystinosis Cystinosin Cystine 
Danon disease LAMP-2 
Cytoplasmic debris and 
glycogen 
Infantile sialic-acid-storage 
disease and  
Salla disease Sialin Sialic acid 
JNCL (Batten disease) CLN3 
Subunit c of the mitochondrial 
ATP synthase 
Mucolipidosis (ML) IV 
Mucolipin-1 
(MLN1) 
Lipids and acid 
mucopolysaccharides 
Niemann-Pick C (NPC) NPC1 (NPC2*) Cholesterol and sphingolipids 
2.4 Mechanisms for LSDs and potential for therapy 
Intra-lysosomal accumulation of undegraded metabolites is characteristic to all 
LSDs. However, despite progress in understanding of the genetic, molecular and 
biochemical bases of LSDs, little is known about the pathogenetic pathways leading 
to the lysosomal accumulation at the cellular level. The extensive variation in 
disease phenotypes indicates that secondary biochemical and cellular pathways must 
be involved. It has been hypothesised that a general “intra-lysosomal protein 
response” mechanism, analogous to the unfolded protein response in the ER 
(resulting from accumulation of misfolded proteins in the ER, and leading to the 
transcriptional activation of ER chaperones and degradative enzymes), exists 
(Futerman and van Meer, 2004; Kaufman, 2002). This would lead to an activation of 
similar response pathways irrespective of the undegraded or unfolded protein. The 
great variability in the accumulating substances and the clinical symptoms between 
the different LSDs, nonetheless, disagree with this hypothesis. Impaired apoptosis 
due to an impaired lysosomal function has also been suggested to underlie the LSDs 
(Tardy, et al., 2004). This would be mediated through different potential (and so far 
mainly theoretical) mechanisms; accumulation of toxic compounds (due to deficient 
metabolism), lack of molecules acting as apoptotic suppressors (e.g. prosaposin), 
impaired lysosome stability, or an uncontrolled activation of lysosomal proteases 
and excessive proteolysis, which would all lead to the activation of the caspase 
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cascade, and consequent induction of cell death. In addition, defective intracellular 
trafficking, defective intracellular signalling, and altered gene expression have also 
been suggested to be causative for LSDs, although the exact cellular pathways 
leading to the lysosomal accumulations and, often to neurodegeneration, are for the 
most part unclear. Most of the LSDs present symptoms originating from the central 
nervous system, which probably indicates the lack of compensatory pathways and/or 
lack of neuronal cell regeneration potential (Futerman and van Meer, 2004; Tardy, et 
al., 2004).    
First treatments for LSDs were mainly symptomatic, such as splenectomy (surgical 
removal of spleen), hemodialysis or renal transplantation. In addition, bone marrow 
transplantation has been utilized to gain some normal, lysosomal-enzyme producing 
cells. As the diagnosis and understanding of the cellular pathogenesis of the diseases 
have improved, advances for specific therapies have been made. Enzyme-
replacement therapy (ERT) was the obvious form of therapy to be developed, as the 
defective enzymes were identified. At present, ERT is approved for Fabry disease 
and MPS I, but it is mainly restricted to diseases with predominating peripheral 
symptoms, as the enzymes used are not able to pass the blood-brain barrier 
(Bengtsson, et al., 2003; Desnick and Schuchman, 2002). In substrate-reduction 
therapy (SRT), the small molecules used act by inhibiting the synthesis of an 
accumulating substance, and are able to cross the blood-brain barrier. SRT has been 
used in sphingolipidoses such as the neuronal subtype of the Gaucher disease, in 
which glycolipids accumulate particularly in the brain (Futerman, et al., 2004). The 
long-term effects of glycolipid depletion, however, have not been established. Great 
promise and potential have been attributed to the development of effective gene 
therapy treatments for the monogenic LSDs.  The preferred treatment would include 
the genetic modification of the patient's own cells in vitro or in vivo to constitutively 
express high levels of the correcting enzyme, which would then become the source 
of the enzyme in the patient. Both ex vivo and in vivo gene transfer methods have 
been experimentally explored, and several of these methods have proved efficient 
for the transfer of genetic material into deficient cells in culture and reconstitution of 
enzyme activity (D'Azzo, 2003). However, application of these methods to humans 
or animal models have been giving inconsistent results, and therefore broader 
understanding of the disease mechanisms and the animal models, as well as 
development of better gene transfer methods will be necessary make gene therapy a 
realistic option for treatment.  
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3. Juvenile neuronal ceroid lipofuscinosis 
3.1 Neuronal ceroid lipofuscinoses (NCLs) 
Neuronal ceroid liposfuscinoses (NCLs) comprise a group of at least eight 
autosomal, recessively inherited, progressive neurodegenerative diseases with onset 
usually in childhood. They occur worldwide and are considered to be the most 
common progressive brain disorders of childhood (Haltia, 2003; Mole, et al., 2005). 
NCL diseases are marked by two histopathological findings: degeneration of nerve 
cells, foremost in the cerebral cortex, and accumulation of autofluorescent ceroid-
lipopigment in both neural and peripheral tissues (Goebel, 1997). Except for the 
newest member of the NCL family, Northern epilepsy (CLN8), typical clinical 
features are shared among the NCLs: visual failure leading to blindness, myoclonic 
epilepsy, dementia of various degrees, pyramidal/extrapyramidal symptoms, and 
ultimately, premature death (Santavuori, et al., 2000). NCLs are divided into four 
main classes based on the age of onset of the disease; infantile (CLN1), late infantile 
(CLN2), juvenile (CLN3) and adult (CLN4, gene not identified). NCLs are enriched 
in Finland and the most common types are JNCL and INCL with incidences of 1:21 
000 and 1:20 000, respectively. LINCL is rare, whereas the Finnish variant LINCL 
is more common (Santavuori, 1988). 
Infantile neuronal ceroid liposfuscinosis (Santavuori-Haltia disease, INCL) is the 
most severe of the NCLs, caused by a deficiency in a lysosomal depalmitoylating 
enzyme activity (palmitoyl protein thioesterase 1, PPT1) (Hellsten, et al., 1996; 
Lehtovirta, et al., 2001; Salonen, et al., 2001; Vesa, et al., 1995). INCL is 
characterized by a normal development to the age of 6-12 months, followed by an 
arrest of mental, cognitive and motor development, severe microcephaly, myoclonus 
and visual deterioration (Haltia, et al., 1973; Santavuori, et al., 1973). The EEG is 
isoelectric by the age of 3 years, and the children die between 9-11 years of age 
(Santavuori, 1973). Late infantile neuronal ceroid liposfuscinosis (Jansky-
Bielschowsky disease, LINCL) is caused by a deficiency of a lysosomal protease 
(tripeptidyl peptidase, TPP1), a member of a serine-carboxyl proteinase family 
(Golabek, et al., 2003; Sleat, et al., 1997). In most cases, epilepsy is the first 
symptom of the disease, other symptoms common to all NCLs, develop slightly later 
(Hofmann and Peltonen, 2001). It is one of the rare lysosomal storage disorders 
caused by a deficiency of a lysosomal protease. In addition to the classic LINCL, 
three variant forms of the late infantile NCL exists: Finnish variant LINCL 
(vLINCLFin, CLN5), CLN6-variant LINCL, and a Turkish variant LINCL (vLINCL, 
CLN7). Clinical phenotype of Finnish variant LINCL (vLINCL) is an intermediate 
between the classic LINCL and JNCL (Santavuori 1982, 1991), and the patients 
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come exclusively from a cluster of 16 Finnish families (Isosomppi, et al., 2002; 
Savukoski, et al., 1998). Subsets of the Turkish variant LINCL patients have been 
shown to have mutations in the CLN8 and CLN6 genes (Ranta, et al., 2004; Siintola, 
et al., 2005), and it is yet to be determined whether the CLN7 locus, assigned for the 
Turkish LINCL, truly exists. The clinical and molecular characteristics of the adult 
NCL (CLN4, Kufs disease) (Berkovic, et al., 1988), CLN6-variant LINCL (Gao, et 
al., 2002; Heine, et al., 2004; Wheeler, et al., 2002), and Northern epilepsy (CLN8) 
(Hirvasniemi, et al., 1995; Hirvasniemi, et al., 1994; Lonka, et al., 2000; Ranta, et 
al., 1999) are described in detail elsewhere.  
To date approximately 160 mutations causing NCL have been described (NCL 
Mutation Data base, http://www.ucl.ac.uk/ncl). The original hypothesis was that 
defects in one gene lead to a classic phenotype and ultrastructure of the storage 
material. However, the genotype-phenotype correlations have proven to be more 
complex than that; some mutations are associated with a phenotype that is of later 
onset, less severe or protracted in its course, or with atypical morphology (Mole, et 
al., 2005). A summary of the classic clinical phenotypes and their variations 
associated with the NCL genes, as well as the major components of the storage 
material and ultrastructural phenotype, are presented in Table 2. 
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Table 2. Classification of the NCLs. Defects in one gene can cause several clinical 
phenotypes. The encoded proteins, the major component of the storage material, and 
ultrastructural phenotype are also presented. GROD, granular osmiophilic deposits; 
FP, fingerprint bodies; RL, rectilinear complex; CL, curvilinear profiles; TM, 
transmembrane. For references, see the text.  
Classification of the NCLs
Clinical types Gene Protein 
Storage 
material Ultrastructure 
INCL, also late 
infantile, juvenile 
and adult inset CLN1 
Lysosomal palmitoyl 
protein thioesterase  
PPT1
Saposins A 
and D GROD 
LINCL, also 
juvenile onset CLN2 
Lysosomal 
tripeptidyl peptidase 
TPP1
Subunit c of 
mitochondrial 
ATP synthase CL
JNCL CLN3 TM-protein CLN3  
Subunit c of 
mitochondrial 
ATP synthase FP (CL, RL) 
ANCL CLN4 Not known 
Subunit c of 
mitochondrial 
ATP synthase FP, granular 
LINCL, Finnish 
variant, also 
juvenile onset CLN5 
Lysosomal soluble 
CLN5 
Subunit c of 
mitochondrial 
ATP
synthase, 
Saposins A 
and D RL, CL, FP 
LINCL, EJNCL, 
Indian/Costa
Rican/Czech 
Gypsy variant 
also juvenile 
onset CLN6 
ER-resident TM-
protein CLN6  
Subunit c of 
mitochondrial 
ATP synthase RL, CL, FP 
LINCL, Turkish 
variant CLN7 Not known 
Subunit c of 
mitochondrial 
ATP synthase RL, CL, FP 
LINCL, Northern 
epilepsy and 
Turkish variant, 
also juvenile 
onset CLN8 
ER-resident TM-
protein CLN8 
Subunit c of 
mitochondrial 
ATP synthase 
CL-like, 
granular 
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3.2 Clinical findings in JNCL 
Juvenile neuronal ceroid-lipofuscinosis (MIM 204200), also called Spielmayer-
Vogt-Sjögren disease or Batten disease, is the most common of the NCLs 
worldwide. The first cases were identified as early as 1826 in Norway (Stengel, 
1826), and similar case reports were published independently by Batten, Spielmayer 
and Vogt nearly a century later in 1903 and 1923 (Haltia, 2003). Characteristic first 
symptom of the juvenile NCL is a progressive visual failure with an age of onset of 
4-8 years (occasionally later), which leads to blindness in most cases during teenage 
years. Mental retardation and cognitive decline begin early but are subtle in their 
course and go often unnoticed until school-age. More pronounced deterioration 
occurs at 8-12 years of age (later in some patients). Epileptic seizures of a 
generalized tonic-clonic (primary or secondary) or complex partial type begin 
between 8-13 years of age. Parkinsonian type of extrapyramidal symptoms (ataxia, 
dysarthria, rigidity, difficulty of movement initiation) develop slowly, and there is 
great variation in the onset (Jarvela, et al., 1997). The JNCL patients become non-
ambulatory at ages of 15-28 years (Santavuori, et al., 2000). Behavioural and 
psychiatric problems are also common, including hallucinations and psychosis 
(Santavuori, et al., 1993). In addition, sleep dysfunction is common in JNCL, and 
occurs in 50-90% of cases (Santavuori, et al., 2000).   
3.3 Neuropathology of JNCL 
The neuropathology of JNCL was well described in the early 20th century, and that 
description remains valid (reviewed in (Hofmann and Peltonen, 2001).  
Macroscopically, the brain is moderately or even severely decreased in weight, and 
the skull bones are thickened due to the brain atrophy. The cerebral cortex is thinner, 
and the white matter is atrophic. Loss of neurons is observed virtually in all parts of 
the brain, but the severity in different areas varies. Reactive astrocytosis, associated 
with the neuronal loss, is also observed. Ballooning and rounding of the neurons due 
to distension caused by the perikaryonal lipopigment, known as the Shaffer-
Spielmayer process, is prominent and especially evident in the cortical neurons of 
the forebrain and cerebellum. Early lesions of specific layers of the cerebral cortex 
have also been documented; more specifically, loss of small stellate neurons in layer 
II, and loss of pyramidal neurons in layers IV and V are seen (Braak and Goebel, 
1978). Consistent with the visual impairment, degeneration of the retinal 
neuroepithelium is evident. In the later stages of the disease, lipopigment-containing 
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cells invade all layers of the retina resulting in almost complete loss of rods, cones, 
and the inner and outer plexiform layers (Goebel, et al., 1974).  
3.4 Neuroimaging findings in JNCL 
Neuroimaging with computer tomography (CT) and magnetic resonance imaging 
(MRI) appears normal in JNCL patients under 10 years of age. Thereafter, slow 
progressive cerebral, and later, cerebellar atrophy appeared in a study sample of 30 
Finnish JNCL patients. Even the youngest patients had a significant increase in 
white matter signal intensity. Reduction in size of corpus callosum and brain stem 
was also observed (Autti, et al., 1996). In conclusion, the MRI findings in JNCL 
were quite unspecific, but absence of them may be of use in differential diagnostics. 
Post-mortem MRI combined with histopathological analysis showed a correlation 
between an increased signal intensity periventricular white matter and severe loss of 
myelin and gliosis in these areas. In addition, reduced signal intensity in thalamus 
and basal ganglia areas was observed, but these did not correlate with 
histopathological findings (Autti, et al., 1997).  
Positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) imaging have demonstrated both pre- and postsynaptic, 
dopaminergic hypofunction in the nigrostriatal area that were in part related to the 
severity of extrapyramidal symptoms (Aberg, et al., 2000; Rinne, et al., 2002; 
Ruottinen, et al., 1997).  
3.5 Neurophysiological findings in JNCL 
The electroencephalogram (EEG) is normal at the early stages of the disease and at 
the age of 8-9 years shows slow, non-specific deterioration (Hofmann SL, 2001).  
Progressive attenuation of amplitudes of cortical somatosensory evoked potential 
(SEP) is a general feature of the NCLs (Santavuori, et al., 2000). In a study sample 
of ten Finnish JNCL patients, the amplitude of SEP potentials was increased, as was 
SEF (somatosensory evoked magnetic fields) studied with magnetoencephalography 
(MEG) (Lauronen, et al., 1997). These results indicated increased thalamocortical 
excitability in the sensorimotor cortex in JNCL.  
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3.6 Intracellular storage in JNCL and its significance to pathology 
The autofluorescent lipopigments accumulating in JNCL are very similar to the age-
related pigments accumulating in normal tissues and their ultrastructure resembles a 
fingerprint (Figure 6). The lipopigment granules have an intense activity of acid 
phosphatase, suggesting an association with lysosomes. This impression has been 
later confirmed by EM studies (Reviewed in (Hofmann and Peltonen, 2001). The 
storage material is already detectable in the prenatal period, and inclusion bodies 
have been reported as early as the first trimester (Conradi, et al., 1989). Since the 
symptoms do not begin until school-age, this suggests, that the neuronal cells and 
tissues are able to tolerate the storage to some extent.  
The major component of the storage material in JNCL is the subunit c of the 
mitochondrial ATP synthase complex (Hall, et al., 1991; Palmer, et al., 1992). ATP 
synthase is a large membrane-embedded enzyme complex composed of a proton-
conducting unit and a catalytic unit. ATP synthase carries out the final phase of the 
oxidative phosphorylation in the inner mitochondrial membrane by catalyzing the 
formation of ATP from ADP and orthophosphate, driven by the proton flow into the 
mitochondrial matrix. Ten to fourteen units of the subunit c, together with a single 
subunit a, compose the hydrophobic proton channel of the ATP synthase, embedded 
into the inner mitochondrial membrane (Berg, et al., 2002).  
Subunit c of the mitochondrial ATP synthase complex also accumulates in other 
lysosomal disorders including mucopolysaccharidosis (MPS) I, II and IIIA, multiple 
sulfatase deficiency, mucolipidosis I, Nieman Pick types A and C, and GM1 and 
GM2 gangliodoses (Hofmann and Peltonen, 2001). However, in these diseases, the 
accumulation is only observed in the central nervous system, whereas in the NCLs, 
also the peripheral cells accumulate the subunit c. This suggests that the 
accumulation of the mitochondrial ATP synthase subunit c is more specific for the 
NCLs than other lysosomal storage disorders. Vacuolated lymphocytes in peripheral 
blood are also a common finding in many LSDs; however, JNCL is the only NCL 
subtype, in which they are found.  
Minor components of the lysosomal storage in JNCL are the two sphingolipid 
activator proteins (saposins) A and D, which activate lysosomal hydrolases involved 
in glycosphingolipid degradation. Saposins A and D as well as the subunit c of the 
ATP synthase are extremely hydrophobic molecules with a tendency to self-
aggregate. It has been shown in the ovine NCL that the amounts of subunit c, its 
insertion into the mitochondrial membrane, and the rate of oxidative 
phosphorylation are normal, suggesting that the specific failure in the NCLs is in the 
degradation of the hydrophobic subunit in the lysosomes (Palmer, et al., 1992). This 
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hypothesis was supported by a human study using LINCL and JNCL brain samples 
(Kominami, et al., 1992). Nonetheless, fundamental question in terms of the 
lysosomal storage still remains to be answered; further studies on the mechanisms of 
cell death are needed to understand whether the neuronal cell death is directly 
caused by the storage, and why are the nerve cells exclusively affected.  
Figure 6. Electron micrograph of the fingerprint type storage material of a JNCL 
patient. Figure courtesy of Dr Juhani Rapola, University of Helsinki.  
3.7 CLN3 gene and mutations 
The CLN3 gene spans a 15-kb region in the chromosome 16p11.2-12.1, consisting 
of 15 exons, which form an open reading frame (ORF) of 1314 bp (Consortium, 
1995). The length of the exons is 47-356 bp, and they conform to the conventional 
AG/GT rule (Breathnach, et al., 1978). Numerous repetitive Alu elements are 
present within the introns and 5'- and 3'-untranslated regions. The 5' region of the 
CLN3 gene contains several potential transcription regulatory elements but no 
consensus TATA-1 box was identified, thereby suggesting that CLN3 is a 
continuously expressed gene (Mitchison, et al., 1997).  
To date, forty disease causing mutations and five polymorphisms of CLN3 have 
been identified and they are fully listed in the NCL Mutation Database 
(http://www.ucl.ac.uk/ncl). The spectrum of mutations include 4 large deletions, 6 
small deletions, 5 small insertions, 10 missense mutations, 9 nonsense mutations, 5 
mutations affecting splice sites and 1 intron change. The most common 1.0-kb 
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deletion that is present on approximately 85% of the disease chromosomes, removes 
exons seven and eight (CLN3Δex7-8), resulting in a frameshift and a premature STOP 
codon. This truncated polypeptide consists of 181 aa that including 28 novel aa in 
addition to the original 153 aa.  
In all cases of NCL caused by mutations in CLN3, visual failure has occurred by ten 
years. However, depending on the mutation type, other symptoms (seizures, motor 
disabilities, mental retardation) may be significantly delayed. In the classic JNCL, 
caused by the 1.0-kb major mutation or by other mutations leading to a truncated 
CLN3 protein, significant mental retardation is evident before the age of ten years, 
extrapyramidal symptoms develop before the age of fifteen, and death occurs 
usually around twenty years of age and no later than twenty-five years. The delayed 
classic JNCL, associated with patients with a compound heterozygous genotype, has 
slower progression of symptoms: mental retardation takes place soon after ten years 
of age, extrapyramidal symptoms after fifteen years of age, and death usually after 
twenty-five years of age (Jarvela, et al., 1997). Protracted JNCL is associated with 
missense mutations (best studied E295K, R334H) that presumably affect less 
important residues of the CLN3 protein, and is markedly milder in phenotype: visual 
impairment and blindness are prominent at an early age but mental and motor 
symptoms are manifested considerably later, usually in the third or fourth decade of 
life.    
3.8 CLN3 protein 
The CLN3 gene encodes a 438-aa transmembrane CLN3 protein with an 
approximate molecular weight of 43 kD (Figure 7). CLN3 is evolutionarily 
conserved from yeast to humans, and it has no homologies to any known proteins. 
Consequently, its function cannot be predicted from the amino acid sequence. The 
topology of CLN3 was long elusive, and prediction programs estimated 5-11 
transmembrane segments. Recently, two experimentally derived topology models 
have emerged. Mao et al. utilized flag-tagged CLN3 and glycosylation mutagenesis 
and postulated that CLN3 has five membrane spanning domains, an 
extracellular/intraluminal N-terminus and a cytoplasmic C-terminus (Mao, et al., 
2003). In contrast, Kyttälä  and Ezaki argued that the N-terminus, the 
large loop and the C-terminus all face the cytoplasm, indicating (five or) six 
transmembrane domains (Figure 7) (Ezaki, et al., 2003; Kyttala, et al., 2004). The 
latter model is supported by stronger evidence, as the experiments were carried out 
in vivo
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3.9 Post-translational modifications of CLN3 
CLN3 protein contains several putative post-translational modification sequences, 
which will be discussed below (Figure 7). Lysosomal proteins are often heavily 
glycosylated in order to avoid proteolysis in the lysosomal lumen. CLN3 protein has 
been predicted to have four putative N-glycosylation sites, two putative O-
glycosylation sites, and two putative glycosaminoglycan sites (Golabek, et al., 
1999). N-linked glycosylation has been demonstrated by Järvelä et al. (Jarvela, et 
al., 1998) and Golabek et al. (Golabek, et al., 1999). The former group showed that 
the molecular weight of an unmodified, in vitro translated CLN3 was ~43 kD, and 
Figure 7. Topology of CLN3 protein according to Ezaki (2003) and Kyttälä 
(2004), with 5-6 transmembrane segments and both N- and C-termini residing 
in the cytoplasm. The reported lysosomal targeting signals, the three putative 
glycosylation sites (antennas) and the eight putative phosphorylation sites 
(spheres) are indicated. The localisations of the most common mutations in 
terms of the topology are marked with the indicated colours. Figure courtesy of 
Dr Jared Benedict, University of Rochester. 
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expression for longer periods of time in COS-1 cells resulted in an apparent 
maturation of the protein, and an appearance of a doublet band of 43- and 45-kD. 
Golabek et al. reported significantly larger band size of 66-kD and 100-kD for 
CLN3 in a study using GFP-tagged CLN3 in Chinese hamster ovary (CHO) cells. 
The discrepancy in terms of the molecular weight of CLN3 may be reflective of the 
different cell lines used in the studies. Moreover, N-linked glycosylation was also 
shown in a study using endogenous mouse Cln3, which also has four putative N-
glycosylation sites (Ezaki, et al., 2003). Treatment of GFP-CLN3 expressing CHO 
cells with tunicamycin, which prevents glycosylation, did not alter the subcellular 
localization of CLN3 (Kida, et al., 1999). The current topology model illustrated in 
Figure 7 supports the existence of three N-glycosylation sites.  
CLN3 has ten serines and three threonines that could potentially act as sites for 
phosphorylation.  Evidence on the CLN3 phosphorylation was provided by a study, 
in which GFP-CLN3 overexpressing CHO cells were exposed to a radiolabeled 
phosphate, and incorporation of phosphates was seen (Michalewski, et al., 1999). 
When the cells were further treated with alkaline phosphatase, the isotopic labelling 
was removed, indicating phosphorylation of some of the potential sites. It was also 
shown that the level of CLN3 phosphorylation can be regulated by several kinases 
(cAMP-dependent kinase, cGMP-dependent kinase, casein kinase II) and 
phosphateases (protein phosphatases I and II), which however, are non-specific in
vitro. Further in vivo studies are needed to determine the exact phosphorylation 
status and sites of CLN3, and the relevance to its function.  
Mannose 6-phosphate residues are essential lysosomal targeting motifs for most 
soluble lysosomal proteins (see chapter 1.2). As would be expected for a lysosomal 
transmembrane protein, CLN3 does not contain any mannose 6-phosphate residues 
(Michalewski, et al., 1999).    
Original predictions of the CLN3 protein sequence suggested two potential lipid 
modification sites: N-myristoylation at the amino terminus and prenylation 
(farnesylation) at the carboxy-terminus (Kaczmarski, et al., 1999; Pullarkat and 
Morris, 1997). Indirect evidence from studies by Ezaki et al. (Ezaki, et al., 2003) 
suggested a modification, possibly myristoylation in the amino terminus, as they 
were unable to sequence the N-terminus by Edman degradation. The authors also 
pointed out that this blockage may well be due to other secondary modifications, 
such as acetylation. The originally predicted prenylation motif (CAAX) at the 
carboxy-terminus (435CQLS438) is undefined (Figure 7) as the current programs 
are no longer able identify it (Phillips 2005). Some experimental evidence, however, 
exists, as in vitro produced GST-tagged CLN3 was observed to be prenylated 
(Kaczmarski, et al., 1999). At a functional level the evidence is controversial; 
mutation of this motif did not affect cell growth or apoptosis, as the native CLN3 did 
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(Persaud-Sawin, et al., 2002), but it did inhibit the complementing action of the 
CLN3 in the functional studies of the knock-out yeast homologue Btn1p (Haskell, et 
al., 2000).   
3.10 Subcellular localization of CLN3 
Endosomal/lysosomal compartment is considered the most likely subcellular 
localization for CLN3/Cln3 in non-neuronal cells, demonstrated by several studies 
(Ezaki, et al., 2003; Golabek, et al., 1999; Haskell, et al., 2000; Jarvela, et al., 1999; 
Jarvela, et al., 1998; Kida, et al., 1999; Kyttala, et al., 2004; Mao, et al., 2003). 
However, several other intracellular localizations have also been proposed for 
CLN3; endoplasmic reticulum (Kida, et al., 1999), Golgi (Kremmidiotis, et al., 
1999), cell membranes and nucleus (Margraf, et al., 1999), and mitochondria (Katz, 
et al., 1997). Prior to this study, neuronal localization of CLN3 had been just 
tentatively examined and it seemed that the protein is trafficked along the neural 
extensions (Jarvela, et al., 1999). There are several potential explanations for the 
controversial reports on the localization of CLN3. Firstly, production of antibodies 
against the full-length CLN3 has been unsuccessful due to its toxicity to bacterial 
expression systems, which has led to the use of peptide antibodies with or without 
affinity purification, which in turn may result in a poor specificity or cross-
reactivity. Secondly, some of the studies did not utilize double labeling techniques 
with subcellular organelle markers, and thus relied on morphological features of the 
cells (Katz, et al., 1997; Margraf, et al., 1999). Thirdly, due to the low endogenous 
level of CLN3, all studies in non-neuronal cells have been conducted using over-
expression systems. Therefore, it should be expected that the consequent, 
unphysiologically high expression levels overload the ER-Golgi biosynthetic route 
leading to the observation of the protein in the ER and Golgi, in addition to its final 
destination. Finally, the diversity of the reports on the intracellular localization of 
CLN3 protein may also suggest that CLN3 has different intracellular localization in 
different cell types.
Confirmation for the endosomal/lysosomal localization of CLN3 in somatic cells 
was obtained from studies demonstrating two lysosomal targeting motifs within the 
cytoplasmic segments (Kyttala, et al., 2004). A conventional dileucine motif (LI) 
was found in the large cytoplasmic loop, preceded by an acidic patch. A novel motif 
consisting of methionine and glycine, separated by nine amino acids, in the carboxy-
terminal tail is also required for the correct targeting. The localization of these 
motifs is shown in Figure 7. On the contrary, it has been also reported that the 
cytoplasmic dileucine targeting motif alone was sufficient to target CLN3 to the 
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lysosomes (Storch, et al., 2004). Furthermore, it has been shown that the lysosomal 
targeting of CLN3 is facilitated by the adaptor complexes AP-1 and AP-3 via its 
dileucine motif (Kyttala, et al., 2005).  
It has also been suggested that CLN3 is localised to the lipid rafts (detergent-
resistant lipid domains) together with cholesterol, palmitic acid and Flotillin-1 
(Rakheja, et al., 2004).    
3.11 Interactions of CLN3 protein 
Since the function of CLN3 is presently unknown, interaction partners would be 
essential in defining the biochemical and cellular pathways at which CLN3 operates. 
Due to the hydrophobic nature of the CLN3, and its toxicity to expression systems, it 
has been very challenging to find true interaction partners. The first yeast-two 
hybrid assays utilizing the full-length CLN3 resulted in no interaction partners 
(Leung, et al., 2001). Currently, after the topology of the CLN3 protein has been 
experimentally determined, yeast two-hybrid screens using the different cytoplasmic 
or lumenal segments have been initiated in two separate research groups and results 
are soon to be expected (Yliannala et al. and Benedict et al., personal 
communications).  
Two NCL proteins are resident of the ER (CLN6, CLN8) and four are trafficked 
through the ER and localise to the endosomal-lysosomal compartments (CLN1, 
CLN2, CLN3, CLN5), and it has been suggested that they are involved in a common 
biochemical and cellular process or pathway. The phenotypic similarities of the 
NCLs further support this notion. The first evidence of such a shared pathway  was 
obtained from a report that demonstrated molecular interactions of CLN5 with 
CLN3 and CLN2 (Vesa, et al., 2002). However, the exact function(s) of these 
interactions are currently not clear.  
3.12 Experimental disease models of JNCL 
3.12.1 Mouse models for JNCL 
The mouse Cln3 and the human CLN3 genes are 82% and 85% identical at nucleic 
acid and amino acid levels, respectively. Similar to the human CLN3, the mouse 
Cln3 also contains an open reading frame of 1314 bp encoding a predicted protein 
product of 438 amino acids, providing a good basis for the generation of gene 
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targeted disease models (Lee, et al., 1996). Two knock-out mouse models and one 
knock-in mouse model have been developed for JNCL. The null mutant knock-out 
mice (Cln3-/-) have been developed by targeted disruption of the Cln3 gene by an 
insertion of a Neo cassette (Katz, et al., 1999; Mitchison, et al., 1999). The Cln3-/-
mice by Katz et al. had JNCL-like autofluorescent accumulations in neuronal and 
other cells from 11 weeks of age; however, no further reports of this mouse model 
exist.  
The Cln3-/- mouse developed by Mitchison et al., and also utilized in this thesis, 
presented classic, autofluorescent JNCL accumulations with multilamellar 
membranous fingerprint profiles, that contained mitochondrial ATP synthase 
subunit c, from one month of age. Delayed neurodegeneration manifesting cortical 
atrophy and thinning, progressive loss of certain hippocampal and cortical 
interneuron populations, as well as presymptomatic gliosis have also been reported 
(Mitchison, et al., 1999; Pontikis, et al., 2004). The specific feature of the Cln3-/-         
mouse as well as other NCL mouse models appears to be a selective loss of 
GABAergic inhibitory interneurons, which occurs many months after the 
accumulation of the autofluorescent storage material (Pontikis, et al., 2004). 
Interestingly, an autoantibody for the glutamic adic decarboxylase (GAD65), 
involved in the synthesis of glutamate, was detected in the sera of the Cln3-/- mice 
(Chattopadhyay, et al., 2002). The inhibitory action of this autoantibody leads to 
increased levels of glutamate, and possibly to increased excitatory stimulus, 
suggested to contribute to the death of the interneurons. In addition, mild 
photoreceptor apoptosis and optic nerve degeneration have been observed 
(Sappington, et al., 2003; Seigel, et al., 2002). High resolution magnetic resolution 
imaging demonstrated a decrease in signal intensity ratio in grey matter regions 
including cortex, hippocampus and cerebellum, tissues where neuronal storage 
accumulation and cell loss have been observed (Greene, et al., 2001). The  Cln3-/-
mice performed poorly in a recent behavioral assessment involving an associative 
learning task (light-cued T-maze test), in spite of normal retinal electrophysiological 
responses, echoing the characteristic learning impairment of the human patients 
(Wendt, et al., 2005). 
To identify affected metabolic pathways, 10-week old Cln3-/- mice have been used 
for three gene expression profiling analyses using the whole brain, cerebellum and 
whole eye. In the whole brain, hundreds of differentially expressed genes were 
found with apparent down-regulation of neurotransmitter metabolism (Elshatory, et 
al., 2003). In the cerebellum, 756 genes were differentially expressed two-fold or 
more with association to neurotransmission, neuronal cell structure and 
development, immune response and inflammation (Brooks, et al., 2003). In the 
whole eye array, 285 genes with altered expression, of which 18 specific to the eye, 
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were observed and further classified into 12 functional classes (Chattopadhyay, et 
al., 2004). In terms of energy metabolism, a shift towards gluconeogenesis and 
down-regulation of genes associated with energy production in the mitochondria 
were observed in the cerebellum and the eye studies, respectively. 
A knock-in strategy was utilized to generate a mouse model harbouring the most 
common patient mutation removing exons 7 and 8, Cln3Δex7-8 (Cotman, et al., 2002). 
This mouse apparently had a more pronounced phenotype with prenatal JNCL-like 
accumulations, degenerative changes in retina, cerebral cortex and cerebellum, 
followed by neurological symptoms and premature death. Studies using cerebellar 
precursor cell lines showed a defect in membrane trafficking, demonstrated with a 
fluorescent dextran uptake experiment, and elongated and dispersedly located 
mitochondria (Fossale, et al., 2004). Stereological analysis of the Cln3Δex7-8 brains 
showed evidence of thalamocortical neuron loss, and profound, localised gliosis in 
the neocortical and thalamic regions (Pontikis, et al., 2005).    
3.12.2 Experimental model organisms for JNCL 
Conservation of the CLN3 gene from yeast to humans has led to the development of 
several experimental model organisms for JNCL. There are two yeast models 
defective of the CLN3 orthologue named BTN1p, in Saccharomyces cerevisiae
(budding yeast) and in Schizosaccharomyces pombe (fission yeast) (Gachet, et al., 
2005; Pearce and Sherman, 1997). The S. cerevisiae Btn1p protein is 39% identical 
and 59% similar to the human CLN3, and localised to the vacuole, analogous to the 
mammalian lysosome. An absence of BTN1p causes an acidification of the yeast 
vacuolar pH at an early growth phase, but CLN3 is able to complement this change 
(Pearce and Sherman, 1998). A pH change in the opposite, alkaline direction has 
been observed in the human patients, indicating that mutations in the CLN3 result in 
disruption of the lysosomal pH (Holopainen, et al., 2001). Gene expression profiling 
of the btn1-Δ strain lacking the BTN1 gene showed an up-regulation in two genes; 
HSP70, involved in the vacuolar pH regulation, and endocytic Btn2p/HOOK1 
protein (Pearce, et al., 1999). A defect in arginine transport out of the vacuole has 
also been demonstrated, and this phenomenon was also complemented by CLN3 
(Kim, et al., 2003). The authors suggested a role for CLN3 in arginine transport out 
of the lysosomes, which however, is not known to be performed by a specific 
transporter in mammalian cells. Nonetheless, the data may suggest a role for CLN3 
in the regulation of arginine transport and/or other small molecules across the 
lysosomal membrane.  
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The CLN3 homologue Btn1p in S. pombe is 30% identical and 48% similar to its 
human counterpart (Gachet, et al., 2005). The btn1-Δ strain cells lacking Btn1p were 
viable but had enlarged and more alkaline vacuoles, which were complemented by 
the overexpression of Btn1p and human CLN3. Btn1p was trafficked via the plasma 
membrane through the early endocytic and prevacuolar compartments to the 
vacuolar membrane in a Ypt7-dependent (homologue of human Rab7) manner. This 
study also suggested a role for the elevated pH in terms of the pathogenesis, as the 
severity of the mutations in btn1 correlated with the pH elevation. In addition, a role 
for Btn1p in the prevacuolar compartments as well as in cytokinesis, the last step of 
the yeast cell cycle, was proposed.  
Caenorhabditis elegans (nematode worm) has three gene homologues to the CLN3,
named cln-3.1, cln-3.2 and cln-3.3. A triple deletion mutant showed decreased 
lifespan but no aberrant lipopigment distribution or accumulation was detected (de 
Voer, et al., 2005). In addition, Drosophila melanogaster (fly) and zebrafish models 
for JNCL are under development (NCL Models Consortium, personal 
communications), and due to the relatively easy and fast genetic manipulation ability 
and phenotype analysis of these model organisms, they are expected to provide an 
essential insight for the analysis of the CLN3 function and interaction partners.   
55
AIMS OF THE PRESENT STUDY  
Prior to this study, the CLN3 gene defective in the JNCL had been identified, 
localization of the corresponding CLN3 protein had been studied in somatic cell 
types, and investigation of the protein in the neuronal cells had been initiated. The 
following aims were addressed in this study: 
• To analyse the mouse Cln3 gene expression and the Cln3 protein 
localization at a tissue level in mouse brain 
• To investigate the subcellular localization of human CLN3 and mouse Cln3 
in primary neuronal cells and tissue fractions 
• To study the intracellular trafficking pathways in the CLN3-deficient 
patient cells 
• To examine the potential interaction between human CLN3 and 
microtubule-binding Hook1, and to study their relation to membrane 
trafficking
• To characterize the Cln3-/- mouse neurons and to investigate the 
mechanisms of the early pathogenesis in the JNCL disease   
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MATERIALS AND METHODS 
1.1 Published materials and methods 
Materials and methods used in this thesis are described in the original publications.  
Table 3.  Published materials and methods used in this study. 
Material or method Original  
publication 
Calcium imaging  III
Cloning of cDNAs and other plasmid constructs I, II 
Co-immunoprecipitation assay II 
Confocal microscopy I, II, III 
Detection of mRNA by in situ hybridization  I  
Dissection and culturing of primary retinal and cortical neurons I, III 
DNA extraction    I, II, III 
Gene expression profiling and data analysis III 
Immunoprecipitation II 
In vitro binding assay (GST pull down)  II 
Lactate concentration of blood III 
Mitochondrial oxygen consumption  III 
Mitochondrial respiratory enzyme chain activity III 
Mouse brain tissue preparation  I, III 
Polyclonal antibody production against synthetic peptide I, II 
Primary fibroblast cultures  II 
Protein detection by immunohistochemistry I, III 
Protein detection by direct and indirect immunofluorescence I, II, III 
Protein detection by Western analysis I, II, III 
Protein production by in vitro translation II 
Protein production in E. coli II 
Quantitation of mRNA by real-time reverse transcription-PCR III 
Receptor-mediated endocytosis assay II 
RNA extraction III 
Semliki Forest virus –mediated gene expression I 
Tissue/Organelle fractionation I 
Transferrin endocytosis and recycling assay II 
Transmission electron microscopy  III 
Transient transfections II 
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1.2 Unpublished methods 
1.2.1 Dextran uptake and intracellular trafficking  
To examine fluid phase endocytosis, JNCL and wild type fibroblasts and were 
preincubated in their maintaining medium for 15 min on ice followed by an 
internalisation of fluorescein, lysine fixable dextran (Molecular Probes, 5mg/ml) for 
10 min at 37 °C. Cells were then washed with PBS and chased for 10, 20, 40 min or 
2 h at 37°C in their maintaining medium, and fixed with 4% paraformaldehyde, 75 
mM lysine, 10 mM sodium periodate in 0,0375 M phosphate buffer pH 6.2 for 90 
min.  Then the cells were either mounted in GelMount directly or stained with 
immunofluorescent markers.   
1.3 Ethical aspects 
The study has been approved by the Laboratory Animal Care and Use Committee of 
the National Public Health Institute, Helsinki. The study has been carried out 
following good practise in laboratory animal handling and the regulations for 
handling genetically modified organisms.  
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RESULTS AND DISCUSSION 
1.  Localization of the CLN3/Cln3 to the neuronal synapses
     (I) 
The drastic symptoms of the JNCL disease are derived from the dysfunction, and 
ultimately degeneration, of the central nervous system, and therefore it is of utmost 
importance to study the CLN3 gene and protein in brain and neuronal cells. Prior to 
this study the endosomal/lysosomal localisation of the CLN3 protein had been 
demonstrated in somatic cells using overexpression systems (Jarvela, et al., 1998). 
In preliminary neuronal studies, the overexpressed CLN3 appeared to localise in the 
neuronal extensions (Jarvela, et al., 1999). The aim of this study was to elucidate the 
endogenous Cln3 gene expression and Cln3 protein localisation at tissue level in 
mouse brain (I, (Luiro, et al., 2001). In addition, we utilised a novel primary 
neuronal system, the retinal neurons, to investigate the endogenous localisation of 
Cln3. Finally, the subcellular localisation of Cln3 was examined with tissue 
fractionation techniques.          
1.1 Cln3 gene and protein in mouse brain 
To study the endogenous expression and localisation of the Cln3 gene and Cln3 
protein in adult mouse brain (2.5- and 6-month-old animals), non-radioactive in situ
hybridization and immunohistochemistry were performed. For the protein analyses, 
a novel polyclonal, mouse-specific peptide antibody against the largest cytoplasmic 
loop of Cln3 was generated (m385/Cln3). Both methods resulted in an essentially 
similar distribution pattern showing that most expression was concentrated on the 
neuronal cells, although not all neurons were labelled. No difference between the 
2.5- and 6-month-old mice was detected in terms of the intensities or distribution of 
Cln3 expression (results only for the 2.5-month-old mice shown). Cln3 mRNA and 
protein were detected throughout the brain, and particularly, in the cerebral cortex, 
hippocampus, cerebellum and several different cerebral nuclei (I, Fig. 1 and 2). High 
expression of Cln3 was seen in the cerebral cortex (CTX) in all cortical layers (I, 
Fig. 1A and 2A). In the hippocampus (HC), Cln3 was expressed in the principal 
cells, pyramidal cells (PC) and granular cells (GC) (I, Fig. 1B). Cln3 
immunopositivity was particularly evident in the PC (I, Fig. 2A-B). In the 
cerebellum, Cln3/Cln3 expression and immunopositivity were strong in the Purkinje 
cell layer (PCL) and in the granular layer (GL), and also detectable in the molecular 
layer (ML). Intracellular localization of Cln3 was tentatively examined and Cln3 
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immunostaining was seen throughout the cell soma and in the neuronal extensions, 
and also at the plasma membrane (I, Fig. 2D) 
1.2 Co-localization of the CLN3/Cln3 with presynaptic proteins in 
neurons
To analyse the intracellular localization of endogenous Cln3 in primary neurons, the 
novel mouse m385/Cln3 antibody was utilized. The antibody was able to detect 
endogenous Cln3 in the retinal neurons prepared from embryonic day (E)14.5–16.5 
mice, but not in the corresponding cortical neurons. This may indicate a higher 
expression level of Cln3 in the retinal neurons and coincides well with the fact that 
blindess is the first symptom in JNCL and common to all patients regardless of their 
mutation type (Munroe, et al., 1997; Santavuori, 1988). Using confocal microscopy, 
localisation of endogenous Cln3 specifically to the neuronal cells was confirmed by 
a co-localisation with neuron-specific mouse anti-tubulin ß III isoform antibody (I, 
Fig. 3A). Cln3 was seen to traffic along the neuronal extensions and was also 
present at the synaptic terminals. This observation was supported by a significant 
co-localisation with presynaptic markers SV2 (I, Fig. 3B) and synaptophysin (SYP). 
Partial co-localisation with the growth-associated protein, GAP-43, (I, Fig. 3D–F) 
showed that Cln3 is associated with axons and neuronal growth cones. However, the 
horizontal XZ-projection of the confocal image indicated that Cln3 and GAP-43 are 
not localized in the exactly same subcellular compartment (I, Fig. 3F, insert). Quite 
unexpectedly, no obvious co-localisation of Cln3 and the lysosomal marker Lamp1 
was observed. Lamp1 was retained in the cell soma whereas CLN3 was also 
trafficked along the neural extensions (I, Fig. 3C).  
Corresponding analysis of overexpressed human CLN3 was performed using retinal 
cultures and SFV-CLN3-mediated expression. Double immunostaining analysis with 
the human CLN3-specific peptide antibody (Jarvela, et al., 1998) and specific 
organelle markers gave similar results to those performed with the endogenous 
mouse Cln3 antibody. Overexpressed CLN3 protein was present in the neurites in 
beads-on-a-string fashion in contrast to uniform ß-tubulin staining (I, Fig. 4A–C). 
Partial co-localization of the human CLN3 with presynaptic SV2 was very similar to 
that of the endogenous Cln3 (I, Fig. 4D–F), although the incomplete overlapping 
suggests that the proteins are do not reside in the entirely same subcellular 
compartment. In line with the endogenous studies, no significant co-localisation 
with the lysosomal marker Lamp1 was found (I, Fig. 4G–I). 
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1.3 Synaptosomal localization of CLN3 
To further analyse the subcellular localization of neuronal Cln3, a systematic 
subcellular fractionation of mouse brain tissue was performed. Firstly, the following 
fractions were prepared: 1000 g post-nuclear supernatant (PNS), 14 500 g
supernatant (S1) and pellet (P1), and 100 000 g supernatant (S2) and pellet (P2). 
Cln3 protein was detected quite uniformly in all fractions. Synaptophysin (SYP) had 
a similar distribution with an emphasis on fractions PNS, P1 and P2, whereas 
lysosomal Lamp1 was mostly detected in P1, as expected (I, Figure 5A). 
Interestingly, both Cln3 and SYP were found as a monomeric as well as a high-
molecular weight complex in P2. This may indicate that Cln3, like synaptophysin,
forms SDS-resistant, insoluble complexes. 
The crude synaptosomal fraction (P1) was purified by a discontinuous sucrose 
gradient to obtain the synaptosomal fraction (S) and the synaptic vesicle (SV) 
fraction. Comparative Western blot analysis of Cln3 and SYP showed that both are 
localised to the purified synaptosomal fraction. However, virtually no Cln3 protein 
was detected in the synaptic vesicle fraction, where SYP was enriched (I, Fig. 5B). 
The lysosomal membrane protein Lamp1 was found enriched in the Percoll step 
gradient for lysosomes (L). As expected from the immunofluorescence analyses, no 
enrichment of Cln3 protein into the lysosomal fraction (L) was found, even though it 
was detected in the L fraction to some extent (I, Fig. 5C). 
This study was the first to describe endogenous Cln3 gene and protein. Cln3 was 
extensively characterised at pathogenetically relevant samples; in mouse brain, 
primary neuronal cells and subcellular fractions. Blindess is the first symptom in 
JNCL and common to all patients regardless of their mutation type (Munroe, et al., 
1997; Santavuori, 1988), and therefore retinal neurons provided an excellent 
research model. Central nervous system is most affected in JNCL disease and 
correspondingly, Cln3 was shown to localise specifically to the neuronal cells in 
brain tissue and primary neuron cultures. In somatic cells Cln3 has been localised to 
the lysosomes (Jarvela, et al., 1998), and two lysosomal sorting signals have been 
identified (Kyttala, et al., 2004). Confocal immunofluorescence analysis and 
subcellular fractionation showed that in neuronal cells and tissues, Cln3 is primarily 
localised to the presynaptic terminals, and more specifically, to the synaptosomes. In 
contrast to PPT1, defective in the infantile NCL (INCL) (Lehtovirta, et al., 2001), 
and presynaptic marker SYP, Cln3 was not detected in the actual synaptic vesicles 
(SVs). The absence of CLN3 protein in the SVs but its presence in the synaptosomes 
and microvesicles in the S2 fraction may indicate a circulating role, which is further 
supported by the previous findings of CLN3 residing in several different subcellular 
compartments in non-neuronal cells. After this study it has been reported that 
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transfected CLN3 localises to the early endosomes in primary rat neurons (Kyttala, 
et al., 2004), and this may indicate a role in the presynaptic endocytosis and/or 
exocytosis. Taken together, our findings indicate that Cln3 is not solely a lysosomal 
protein but has a yet unknown function at the neuronal synapses. 
2. CLN3 connected to cytoskeleton and endocytic 
membrane trafficking (II, unpublished) 
This study was initiated in response to the observations in the yeast knock-out model 
for CLN3, btn1-Δ, showing that deletion of BTN1, the yeast orthologue of CLN3,
leads to increased expression of BTN2 (Pearce, et al., 1999). BTN2 encodes Btn2p, a 
proposed homologue to a human Hook1 and Drosophila hook. At the starting stages 
of this work, hook was known to regulate endocytosis in Drosophila, more 
specifically, the maturation of the multivesicular bodies and the transport of cargo to 
the late endosomes and lysosomes  (Kramer and Phistry, 1996; Kramer and Phistry, 
1999; Sunio, et al., 1999). During the course of this study, it was reported that the 
human Hook1 belongs to a novel microtubule-binding family of Hook-proteins 
(Hook1-3), and has an unspecific cytosolic localisation (Walenta, et al., 2001). The 
aim of the study was to examine the proposed interaction of CLN3 and Hook1 in the 
mammalian system. Moreover, endocytosis and intracellular membrane trafficking 
in the JNCL patient cells were explored (II, (Luiro, et al., 2004). 
2.1 Effect of CLN3 on the Hook1 protein 
Analyses of the putative interaction of CLN3 and Hook1 were begun using double-
immunofluorescence stainings and confocal microscopy. In transfected Hela cells, 
Hook1 was distributed uniformly throughout the cytoplasm in small punctuate 
structures (II, Fig. 1G) that did not co-localize with any of the tested immunological 
markers for various subcellular compartments (early endosomes, late endosomes, 
lysosomes, ERGIC, Golgi). EGFP-CLN3 fusion protein generated for this study co-
localised substantially with the lysosomal Lamp1 antibody, similarly to the native 
protein analysed in previous studies (II, Fig. 1A-C) (Jarvela, et al., 1998). However, 
co-expression of Hook1 and CLN3 caused a dramatic change in the Hook1 
subcellular localisation; it appeared in large dot-like structures (II, Fig. 1D-F). The 
formation of the dotted structures was also observed using another cells line, COS-1 
cells, and when native CLN3 was co-expressed with Hook1. However, co-
expression of another lysosomal membrane protein sialin, was not sufficient to cause 
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this phenomenon, implicating that the effect is specific to the CLN3 overexpession 
(II, Fig. 1G-I). 
Pulse-chase and immunoprecipitation analysis clarified our observations, as Hook1 
no longer was immunoprecitable upon co-expression with CLN3 (II, Fig 2A). The 
same phenomenon was observed when Hook1 was co-expressed with the deletion 
mutant form of the CLN3 (CLN3 ex7–8) or with a point mutant form causing milder 
phenotype, CLN3E295K (II, Fig. 2B). In contrast, when Hook1 was co-transfected 
with an empty vector or sialin, it immunopricipitated normally as a ~85 kDa protein. 
This was observed with three different Hook1 antibodies and it suggests that upon 
co-expression with CLN3, Hook1 is found in aggregates in which the antigenic 
epitope is hidden or lost. It has been shown that Hook1 binds microtubules with its 
conserved amino terminal domain (Walenta, et al., 2001). We were able to 
demonstrate that microtubule-depolymerizing agent nocodazole induced similar dot-
like Hook1 aggregates as did CLN3, suggesting that CLN3 overexpression detaches 
Hook1 from the microtubules (II, Fig. 2C). 
2.2 Defective endocytosis in JNCL fibroblasts
Due to the dramatic influence of CLN3 overexpression on the Hook1 protein and the 
proposed function of Drosophila hook in endocytosis, fluid phase endocytosis 
(macropinocytosis) and two different types of receptor-mediated endocytosis were 
examined in the CLN3-deficient JNCL patient cells. 
We first examined the fluid phase endocytosis by analysing the uptake and transport 
of fluorescent dextran in JNCL and wild type (wt) fibroblasts (Figure 8). The cells 
were allowed to internalize fluorescein (FITC) dextran for 10 minutes and then 
either fixed directly or chased for 10, 20, 40 or 120 minutes followed by fixation 
(20-minute chase shown). After internalisation period, dextran was detected in the 
early endosomes in the wt cells. After 20- and 40-minute chase periods, the dextran 
was predominantly seen in the late endosomes and lysosomes (Figure 8). In contrast, 
in the JNCL cells dextran did not co-localize with the early endosomal marker 
EEA1 or the lysosomal marker Lamp1 despite extended incubation periods up to 
two hours, indicating a mislocalization and dysfunction of the fluid phase endocytic 
pathway. To investigate whether the FITC-dextran was mislocalized to the recycling 
endocytic route, the dextran assay was performed concurrently with a transient 
transfection of pEGFP-Rab11, which served as a marker for recycling endosomes. 
However, no co-localization of FITC-dextran with the Rab11 was observed, and 
therefore, with the recycling endosomes either (data not shown). These unpublished 
findings were later supported by studies using immortalised cerebellar cells from the 
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Cln3Δex7-8 knock-in mouse (Fossale, et al., 2004). No double-immunofluorescence 
analysis was performed by Fossale et al., but it was observed that after 15-minute 
incubation, FITC-dextran localised to small, scattered vesicles throughout the 
cytoplasm in the Cln3-deficient cells. In contrast, the wt and heterozygote cells 
displayed brightly stained, large endocytic vesicles that were clustered in the 
perinuclear region. Recently, novel endocytic pathways and organelles have been 
identified (Chapter 1.2), and it would be interesting to examine whether these routes 
are involved in the observed mislocalization of dextran in the JNCL cells.   
Figure 8. Analysis of the fluid phase endocytosis by internalizing fluorescent 
dextran (green) for 10 min, and chased for 20 min. (A-B) In the wt cells, the 
dextran had already passed the early endosomes identified with the EEA1 
antibody (red), and co-localised predominantly with the Lamp1-marker (red) 
for the the lysosomes. (C-D) In contrast, in the JNCL cells, the dextran co-
localized neither with the EEA1 (red) nor with the Lamp1 (red), indicating a 
mislocalisation to an unknown compartment. 
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Receptor-mediated endocytosis was examined with two marker molecules, 
biotinylated transferrin and fluorescent low-density lipoprotein (BODIPY FL-LDL). 
To investigate the receptor-mediated endocytosis and the recycling endocytic 
pathway, we analysed the uptake and recycling of transferrin using biotinylated 
transferrin and a solid phase assay. For the uptake studies, the biotin–transferrin was
bound to the cell surfaces on ice and the internalization at 37°C at two-minute 
intervals up to 10 min was analysed. No difference in terms of the transferrin 
endocytosis between the JNCL cells and the WT cells was observed (II, Fig. 3A). 
For the recycling assay, the endosomes were first loaded with the biotin–transferrin
at 17°C, and then transferred to 37°C at which the consequent recycling at indicated
time points was measured. Results from three independent experiments showed that 
the recycling of biotinylated transferrin was increased in the JNCL cells (II, 
Fig. 3B).  
To examine receptor-mediated endocytosis and the degradative endocytic pathway,
the trafficking of fluorescent low-density lipoprotein (BODIPY FL-LDL) was 
analysed. To up-regulate the LDL receptor expression on the cell surface, the JNCL 
and WT fibroblasts were starved in lipoprotein-free medium overnight. After 
lipoprotein starvation the cells were allowed to internalize BODIPY FL-LDL for 
30 min and either fixed immediately (time point 0) or chased for 40 min or 2 h and 
analysed by confocal microscopy. It was observed that the trafficking of LDL was 
markedly delayed in the JNCL cells as compared to the WT. In the WT cells, LDL 
had passed the EEA1-positive early endosomes (II, Fig. 4A), and predominantly co-
localized with the late endosomal (LE)/lysosomal marker LBPA already after the 30-
min uptake period (II, Fig. 4B). In comparison, in the JNCL cells LDL was found 
exclusively in the EEA1-positive early endosomes at this time point and no co-
localization of the LDL and LBPA was detected (II, Fig. 4C-D), indicating a delay in 
the degradative endocytic pathway. However, after 2 h of chase, BODIPY FL-LDL 
had partially reached the LE/lysosomes also in the JNCL cells (II, Fig. 4E-F). 
Defects in endocytosis and membrane trafficking have been reported to underlie 
numerous human diseases (reviewed in (Aridor and Hannan, 2000; Aridor and 
Hannan, 2002). Defect in the late steps of endocytosis and an increased transport of 
cargo into the lysosomes has been demonstrated in another lysosomal storage 
disease, mucolipidosis IV (Chen, et al., 1998), and a delay in the late steps of 
endocytosis was illustrated in infantile NCL (Ahtiainen, et al., 2006). Additionally, a 
defect in the lysosomal degradation of arylsulfatase A was demonstrated in the 
CLN6-variant form of LINCL (Heine, et al., 2004). The observed defects in the 
membrane transport in the JNCL cells may be directly due to the CLN3-deficiency, 
or alternatively it may be connected to the potentially impaired function of Hook1 
and the microtubule cytoskeleton. We have also observed that the position of 
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lysosomes is more perinuclear in the JNCL cells, compared to the wt, which 
provides additional evidence of dysfunctional microtubule cytoskeleton (Luiro et al.,
unpublished observations). Defective membrane trafficking undoubtedly affects the 
neurodegenerative course of these disorders, but the exact mechanisms of action 
remain to be solved.  
2.3 Interactions of Hook1 with CLN3 and the Rab proteins 
Potential interactions of the CLN3, Hook1 and the endocytic machinery were further 
elucidated by biochemical assays. A weak interaction between the cytoplasmic, in
vitro translated Hook1 and two of the cytoplasmic domains of the CLN3 (amino
acids 1–33, 232–280), produced as GST fusion proteins, was demonstrated (II, 
Fig. 5A). Lumenal domain of CLN3 (amino acids 56–97) and bare GST protein were 
used as negative controls. Densitometric analysis of three separate autoradiograms 
showed that when compared with the GST vector alone, the binding of the 
cytoplasmic domains to Hook1 was significant for both the N-terminal region 
(amino acids 1–33; P=0.03) and the cytoplasmic loop (amino acids 232–280; 
P=0.03) (Fig. 5B). Due to the insoluble nature of GST-Hook1 fusion protein, we
were unable to confirm the interaction vice versa. Although the observed interaction 
of CLN3 and Hook1 was weak, and a possibility of a third party involved remains, 
the findings of this study altogether linked CLN3 to the microtubule cytoskeleton. It 
was later reported that the Hook1 interacts with Ankyrin G, an adaptor involved in 
the actin-spectrin cytoskeleton (Weimer, et al., 2005), and this further strengthens 
the cytoskeletal link for CLN3.  
As Btn2p, the Hook1 homologue in yeast, has been genetically linked to the Ypt/Rab 
proteins (Chattopadhyay, et al., 2003), we explored putative interactions of Hook1 
and CLN3 with the major endocytic Rab proteins (Rab7, Rab9 and Rab11) in 
mammalian cells. The non-endocytic Rab24 was used as a negative control. Hook1 
or CLN3 was co-expressed with the individual GFP-tagged Rab proteins in COS-1 
cells, which were then subjected to immunoprecipitation with a monoclonal GFP
antibody conjugated to agarose beads, and subsequently analysed by western 
blotting with an antibody specific for Hook1 or CLN3. Hook1 was found to 
specifically interact with Rab7, Rab9 and Rab11 but not with Rab24 (II, Fig. 6A and 
B). In contrast, we were not able to demonstrate interactions between CLN3 and the 
Rab proteins using this method (data not shown). To visualize these interactions, a 
confocal immunofluorescence microscopy analysis of the co-transfected proteins 
was performed. Co-localisation of Rab7 and Hook1 was observed upon co-
expression, and their subcellular distribution appeared altered (II, Fig 7A-B left). In 
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contrast, when co-expressed with Rab9, Hook1 appeared to retain its normal
cytoplasmic localization and Rab9 distribution appeared unaltered when co-
expressed with Hook1 (II, Fig. 7A-B, right). Similarly, there was no change in the 
subcellular distribution of Hook1 and Rab11 when expressed together (data not 
shown). The novel interactions of Hook1 and the endocytic Rabs, demonstrated 
here, are of high cell biological significance delineating the versatile role of the Rab 
proteins. Rab proteins, originally thought to function primarily in the tethering and 
docking of transport vesicles to their target membranes, have an increasingly 
diversifying role in the cell, including interactions with cytoskeletal elements 
(Chapter 1.1), and this was reinforced by this study. Our findings linking the 
microtubule-binding Hook1 to membrane trafficking and fusion events were 
supported by a nearly simultaneously published study demonstrating Hook1 
interaction with mammalian Vps18, a component of the mammalian HOPS complex 
involved in membrane tethering and fusion (Richardson, et al., 2004). Recently, a 
novel Hook-related protein family (HkRP) has been discovered, from which the 
authors suggest the Hook proteins have evolved (Simpson, et al., 2005). The HkRP 
family shares the general structure of the Hook proteins; a coiled-coil central region, 
a microtubule-binding N-terminus and a potentially membrane-associated C-
terminus. HkRP1 was proposed to have a role in endocytosis at the level of the early 
endosomes, potentially in the process of tubulation (Simpson, et al., 2005).  
This study established a connection between CLN3, the microtubule cytoskeleton 
and endocytic membrane trafficking. It demonstrated that CLN3 overexpression has 
profound effects on Hook1 localisation and its ability to be immunoprecipated. A 
weak interaction between the two cytoplasmic segments of CLN3 and the 
microtubule-binding Hook1 was also shown, which accounts for the first interaction 
partner for CLN3 outside the NCL protein family. The mechanistic basis for this 
interaction remained to be solved, but it was demonstrated that microtubule-
depolymerizing drug nocodazole causes a similar effect on the Hook1 localisation, 
suggesting that CLN3 overexpression may also dissociate Hook1 from the 
microtubules. The role of the observed defects in the endocytic membrane 
trafficking in the central nervous system will be of great interest to investigate, and 
will provide new clues of the pathogenesis of JNCL. 
3. Fundamental metabolic pathways affected in the Cln3-/-
neurons (III) 
The genetic background of JNCL disease was discovered already in 1995 
(Consortium, 1995), however, the affected cellular and biochemical downstream 
processes have remained elusive. Global gene expression profiling combined with 
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statistical and pathway analysis is a powerful tool to analyse these. For this purpose, 
three microarray studies of the whole brain, cerebellum and retina of the Cln3-/- mice 
had been previously performed (Brooks, et al., 2003; Chattopadhyay, et al., 2004; 
Elshatory, et al., 2003). These studies had utilized adult mice and whole tissues, 
which resulted in a massive number of differentially expressed genes, of which a 
large proportion clearly described the full-scale phenotype. In order to find the early 
affected metabolic pathways, we utilized embryonic Cln3-/- cortical neurons and 
wild type control neurons as our specific disease model (III, Luiro et al. 2005, 
submitted). 
 3.1 Comparative gene expression profiling reveals three major 
pathways affected 
Gene expression analysis of approximately 14,000 well-characterized mouse genes 
in the Cln3-/- cortical neurons and wild type controls identified 88 statistically 
significant, differentially expressed genes at a false discovery rate of 3.6%. Of these, 
70 genes were significantly up-regulated genes and 18 genes were significantly 
down-regulated (III, Table 1). The most up-regulated genes were Gnb1, G protein 
(guanine nucleotide binding) beta 1 subunit, and synuclein α, with fold changes 
(FC) of +12.88 and +9.85, respectively. The most down-regulated gene was 
dynactin 5 (FC -4.22), a relatively uncharacterized subunit of the dynactin complex 
that interacts with cytoskeletal components such as dynein and the microtubules. 
These findings were confirmed by quantitative real-time RT-PCT (III, Fig.2) 
Further categorization using the publicly available Gene Ontology Tree Machine 
tool-kit according to Gene Ontology (GO) classifications (Ashburner, et al., 2000) 
yielded three major pathways or structural components with significantly more 
genes observed than expected: mitochondrial glucose metabolism, the cytoskeleton 
and synaptosomal compartment (P<0.01; III, Fig. 1). These pathways were 
systematically analysed as described below. 
3.2 Slight mitochondrial dysfunction in Cln3-/- mice 
The mitochondrial function and glucose energy metabolism in the Cln3-/- mice was 
analysed with three methods. Firstly, the activities of the mitochondrial respiratory 
chain enzymes I-IV were slightly decreased in the Cln3-deficent mice (III, Fig. 3B). 
Correspondingly, the oxygen consumption of freshly isolated mitochondria from 
68
two Cln3-/- mouse brains was also slightly lower compared to the wt control brains 
(III, Figure 3A). This was determined at baseline and in response to the following 
components or inhibitors of the mitochondrial energy production: ADP, (1) pyruvate 
and malate, (2) succinate and rotenone, (3) ascorbate and TMPD, (4) palmitoyl CoA, 
and (5) α-ketoglutarate. Thirdly, dysfunction of the mitochondrial respiratory chain 
could lead to an increased anaerobic energy production. This would lead to a 
consequent increase in the blood lactate concentration, thus providing indirect 
evidence of abnormal mitochondrial function. Therefore, we measured the lactate 
concentration in blood of six Cln3-/- mice and wt controls. No difference was 
observed, which indicates that at a systemic level, the Cln3-deficient mice are able 
to compensate the observed up-regulation of glycolysis of the Cln3-/- neurons.  
Finally we examined the distribution and morphology of the mitochondria in the 
Cln3-/- neurons using confocal and transmission electron microscopy (TEM). Light 
microscopy of fluorescently labelled mitochondria showed no gross differences in 
the intraneural distibution between the Cln3-/- neurons and wt controls (III, Figure 
4A-B). However, at an ultrastructural level, the size of the mitochondria in the 
CLN3-deficient neurons appeared larger, although some normally sized 
mitochondria were also present. To further analyze this, we performed transmission 
electron microscopy and quantified the area and length of the mitochondria using 
point and intersection counting method (Griffiths and Hoppeler, 1986), which 
demonstrated that the average size of mitochondria was larger in the Cln3-/- neurons 
than in the wt neurons (P=0,016) (III, Fig. 4C-E).       
3.3 Down-regulation of the dynamic microtubular plus-end component 
in the Cln3-/- neurons 
CLN3 has been linked to the microtubule cytoskeleton via the interconnection to the 
microtubule-binding Hook1 protein (II), and the connection to cytoskeleton was 
enhanced by the results from the neuronal gene expression study. The general 
morphology and ultrastructure of the microtubule and actin cytoskeletons appeared 
unaffected, examined by confocal immunofluorescence microscopy and TEM (III, 
Fig. 6A-G). However, immunohistochemical analysis of the most down-regulated 
gene complex, dynactin, using an antibody for its microtubule-binding part 
p150Glued, showed that the down-regulation was evident also at protein level (III, 
Figure 5 A-C). Dynactin plays a major role in the plus-ends of the microtubular 
networks (Schroer, 2004), and the importance of the plus-end function in Cln3-/-
neurons was further emphasized by the significant up-regulation of the Clasp2 gene, 
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encoding CLIP (cytoplasmic linker protein) associating protein 2. Clasp 2 encodes a 
conserved microtubular plus-end tracking protein (+TIP) that is involved in 
stabilizing a subset of microtubules at highly specific intracellular sites in response 
to signalling indicators, for instance at the neuronal growth cones (Galjart, 2005) 
3.4 Evidence of dysfunction in the calcium-mediated synaptic 
transmission 
The pathway analysis highlighted the importance of the synaptosome compartment 
in Cln3-/- neurons. This coincides well with our previous fractionation studies, in 
which Cln3 was enriched in the synaptosomes but not in the synaptic vesicles (I) 
The most up-regulated gene in the gene expression profiling was Gnb1, a beta 1 
subunit (Gbeta1) of the G protein complex, which is also localised in the presynaptic 
areas of neuronal cells. It forms a stable complex Gβγ with the gamma subunit and 
functions as the most important negative regulator of the N-type voltage-gated Ca2+
channels at the presynaptic termini (Clapham and Neer, 1997; De Waard, et al., 
1997; Garcia, et al., 1998).  
Immunohistochemical analysis of the G beta 1 in the Cln3-deficient brain, relative to 
the wt brain, showed an abundant expression throughout the brain with an increased 
signal intensity in the cortical layers I and II in the Cln3-/- mice (III, Figure 7 A-C). 
To explore the potential functional consequences of this up-regulation to the 
synaptic function, calcium imaging techniques were utilized. It was observed that 
the depolarization activity of the Cln3-/- neurons was indistinguishable from the wt, 
indicating that they form functional synapses in cultures. The depolarization with 
selective blockers for the N-type or L-type Ca2+ channels also appeared to be similar 
in both cell types. However, when the N-type calcium channels were selectively 
blocked with ω-conotoxin GVIA, the recovery from the depolarization was 
significantly slower in the Cln3-deficient neurons, indicating a prolonged period of 
higher intracellular Ca2+ (III, Figure 8 A-C).
Animal models are especially valuable in studying neurological disorders, as the 
supply of the relevant patient tissue material is understandably limited. When the 
pathogenesis is unknown, gene expression profiling is a powerful tool in identifying 
and analysing the biochemical and cellular pathways leading to the observed 
phenotype. The type and age of the samples must, however, be carefully determined, 
as even small spatial and temporal differences may divert the results. In a complex 
structure such as the brain, spatially unspecific sample (e.g. the whole brain) may 
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hide some small but significant variation. Similarly, in a progressive disease, if the 
age of the sample is too old, gene expression profiling may become mainly 
descriptive of the phenotype. To identify pathways significant in the early 
pathogenesis, we used embryonic, primary neuronal cultures as a disease model, and 
found three affected pathways or cellular compartments.  
Prior to this study, mitochondrial dysfunction (Das and Kohlschutter, 1996; Das, et 
al., 2001; Dawson, et al., 1996) and abnormal morphology (Zeman, 1970) had been 
reported in the JNCL patients. In addition, elongated mitochondria had been shown 
in the Cln3Δex7-8 knock-in mice (Fossale, et al., 2004). Mitochondrial dysfunction 
may predispose to neurodegeneration per se (Brini, 2003). However, it has been 
shown that the mitochondrial trafficking and function are highly dependent of the 
microtubules (Morris and Hollenbeck, 1995; Rappaport, et al., 1998), and that 
disruption the dynactin-dynein complex leads to branched, elongated mitochondria 
(Varadi, et al., 2004). Therefore, it may well be that the observed abnormalities in 
the microtubule cytoskeleton precede the mitochondrial damage in the Cln3-/-
neurons.  
The dynein-dynactin complex also has an essential role in neuronal synapses. It is 
primarily responsible for the axonal retrograde movement (LaMonte, et al., 2002), 
and it is also required for synapse stabilization in Drosophila (Eaton, et al., 2002). 
Hypothetically abnormalities in the dynactin function may underlie the synaptic 
disturbances in Cln3-/- neurons. It was observed by the calcium imaging experiments 
that Cln3-deficiency may lead to dysfunctional regulation of calcium-mediated 
synaptic transmission. This may also be due to the direct inhibitory effect of Gβγ,
up-regulated in Cln3-/- neurons. Gβγ has a specific and direct inhibitory effect on the 
N-type Ca2+ channels and it also regulates synaptic vesicle fusion events via binding 
to the t-SNARE component SNAP-25 (Blackmer, et al., 2005; Gerachshenko, et al., 
2005). Impaired membrane trafficking has been demonstrated in the JNCL patient 
cells (II), and the synaptosomal membrane fraction, in which Cln3 is localised (I) 
contains the endosomes involved in the SV recycling. Therefore Cln3 may be 
involved in the synaptic endocytosis or exocytosis. In vivo microscopy and 
electrophysiological experiments on Cln3-/- neurons or brain slices will be crucial in 
examining this.  
In conclusion, a systematic analysis of the indicated pathways revealed a slight 
dysfunction of the mitochondria, cytoskeletal abnormality in the microtubule plus-
end compartment, and an impaired recovery from depolarizing stimulus when 
specific N-type Ca2+ channels were inhibited, thus leading to a prolonged time of 
higher intracellular Ca2+. All these pathways are interrelated, but the primary 
pathway to be affected remains to be determined. It has been shown that axon 
degeneration precedes, and sometimes causes neuronal death (Ferri, et al., 2003; 
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Fischer, et al., 2004; Li, et al., 2001; Stokin, et al., 2005). A recent study of the slow 
Wallerian degeneration mutant (Wlds) mouse showed that impaired axonal transport 
from the cell body, mitochondrial dysfunction, and an increase in intra-axonal 
calcium concentration converged into a common pathway that led to calpain-
mediated axonal degeneration (Coleman, 2005). The exact mechanisms of neuronal 
death in JNCL are not clear, and apoptotic and autophagocytotic mechanisms have 
been proposed (reviewed (Mitchison, et al., 2004). Further studies of the animal 
models should reveal whether axonal degeneration mechanism plays a role in the 
neurodegeneration in JNCL.  
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CONCLUSIONS AND FUTURE PROSPECTS 
This study was initiated during the flourishing era of genetics, culminating in the 
completion of the Human Genome Project (HUGO) in February 2001 (Lander, et 
al., 2001; Venter, et al., 2001). Due to the advances in molecular genetics, nearly all 
the genes behind the NCL diseases have been discovered and numerous mutations 
have been identified. The focus of research has shifted towards cell biological 
processes and proteomics, which this thesis also addressed. However, despite the 
years of study concerning the genetic, molecular and biochemical bases of NCLs 
and lysosomal storage disorders, the exact pathological mechanisms and down-
stream events that lead to the intra-lysosomal pathology and neurodegeneration 
remain to be identified.  
Evolutionary conservation of the CLN3 protein across species has enabled the 
generation of mouse models and experimental model organisms for JNCL, and these 
will be at the core of solving the pathogenesis of JNCL. Development of systems 
biology approaches and high-throughput methods in cell biology, metabolomics and 
proteomics will contribute to our knowledge of the affected cellular routes, and 
pinpoint pathways for further analysis using precise methods of cell biology.  
The major findings of this thesis include the synaptosomal localisation of 
CLN3/Cln3 in neuronal cells, the connection of CLN3 to the microtubule 
cytoskeleton, and the demonstration of defects in the endocytic membrane 
trafficking in the JNCL patient cells. These findings were confirmed, and novel 
affected pathways, relevant to the JNCL disease, were discovered by modern high-
throughput methods. Studies from other neurodegenerative diseases suggest that  
dysfunctional mitochondrial energy production, impaired axonal trafficking, and an 
increased intra-neuronal Ca2+, all potentially present in the Cln3-/- mouse neurons, 
may together be sufficient to initiate a neurodegenerative process (Coleman, 2005). 
It is not currently clear whether this is the mechanism of neuronal cell death in the 
JNCL disease, and more primary, defective intracellular pathway(s) may be present.  
Regardless, further studies utilizing neuronal tissues and cells, central to the 
pathology, will be needed. Logical continuation for these studies will be the use of 
in vivo methods in live neurons, such as videomicroscopy and electrophysiological 
methods, some of which have already been initiated.  
The exact function of CLN3 protein remains yet to be solved, although some clues 
have been obtained. Proposed functions for CLN3 include lysosomal acidification, 
degradation of proteins, small molecule transport, organelle fusion and apoptosis 
(reviewed in (Phillips, et al., 2005). Identification of interaction partners will greatly 
73
enhance our knowledge, although it is clear that not all interaction partners and/or 
functions of CLN3 will be equally relevant for the development of JNCL. In the 
light of the current data, CLN3 is localized to microvesicles of the endosomal 
pathway at the presynaptic terminals of nerve cells (Figure 9). The synaptosomal 
localisation of CLN3 as well as the demonstrated impairment of the endocytic 
membrane trafficking in the patient cells suggests a role for CLN3 in the clathrin-
mediated endocytosis that occurs via an endocytic intermediate (step 9). The details 
of this function are elusive, but both yeast and human studies have suggested that 
CLN3 functions in the acidification of the vacuoles. On the other hand, movement 
of these vesicles occurs along the microtubules, and dysfunction of CLN3 and its 
interaction partners may affect the vesicle motility, and thereby impair synaptic 
vesicle endocytosis. Abundance of tightly regulated ion channels and pumps is also 
present at the nerve terminal, and a transmembrane protein such as CLN3 could, in 
principle, function in the transport of ions or solutes across the cell membrane. This 
model gained support from a reported phenotypic similarity in between the Cln3 and
the CLC-7 knock-out mice, defective in a chloride ion channel CLC-7 in late 
endosomes and lysosomes (Kasper, et al., 2005). The CLC-7 mice dislayed a similar 
lysosomal accumulation and neurodegeneration, which  were more pronounced than 
in the previously reported CLC-3 knock-out mice (Kasper, et al., 2005; Stobrawa, et 
al., 2001). CLN3 does not, however, have any homology to the chloride channels, 
and thus it is more likely that CLN3 would function perhaps in the regulation of the 
Cl- ion transport rather than be a transporter per se. Finally, calcium is the key 
mediator of nerve cell signal transduction, and this thesis provided some evidence 
that CLN3 may directly or indirectly have a role in Ca2+-mediated synaptic 
transmission. Analysis of CLN3 with respect to the synaptic proteins, in particular 
those with calcium binding capability, and the details of synapse function will 
provide essential information of its vital action. This will not only gradually create a 
detailed picture of the progressive neuronal degeneration underlying JNCL but will 
be applicable to other neurodegenerative disorders as well. The present experimental 
advances will later become the future therapeutic leads.  
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Figure 9. Hypothetical role for CLN3 in the synaptic endocytosis. MT, 
microtubulus.  
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